



Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution

Anna Valeria Samarelli^{1,2†}, Roberto Tonelli^{1,2,3†}, Irene Heijink⁴, Aina Martin Medina⁵, Alessandro Marchioni^{1,2}, Giulia Bruzzi^{1,2}, Ivana Castaniere^{1,2,3}, Dario Andrisani^{1,2,3}, Filippo Gozzi^{1,2,3}, Linda Manicardi^{1,2}, Antonio Moretti^{1,2}, Stefania Cerri^{1,2}, Riccardo Fantini², Luca Tabbi², Chiara Nani², Ilenia Mastrolia⁶, Daniel J. Weiss⁷, Massimo Dominici^{8*‡} and Enrico Clini^{1,2‡}

OPEN ACCESS

Edited by:

Anna Dmitriyevna Krasnodembskaya,
Queen's University Belfast,
United Kingdom

Reviewed by:

Helen Parfrey,
Royal Papworth Hospital NHS
Foundation Trust, United Kingdom
Amiq Gazdhar,
Bern University Hospital, Switzerland
Andreas Guenther,
University of Giessen, Germany

*Correspondence:

Massimo Dominici
massimo.dominici@unimore.it

†These authors share first authorship

‡These authors share senior
authorship

Specialty section:

This article was submitted to
Respiratory Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 08 April 2021

Accepted: 21 June 2021

Published: 05 July 2021

Citation:

Samarelli AV, Tonelli R, Heijink I,
Martin Medina A, Marchioni A,
Bruzzi G, Castaniere I, Andrisani D,
Gozzi F, Manicardi L, Moretti A, Cerri S,
Fantini R, Tabbi L, Nani C, Mastrolia I,
Weiss DJ, Dominici M and Clini E
(2021) Dissecting the Role of
Mesenchymal Stem Cells in Idiopathic
Pulmonary Fibrosis: Cause or Solution.
Front. Pharmacol. 12:692551.
doi: 10.3389/fphar.2021.692551

¹Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children and Adults University Hospital of Modena and Reggio Emilia, Modena, Italy, ²University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy, ³Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy, ⁴University of Groningen, Departments of Pathology & Medical Biology and Pulmonology, GRIAC Research Institute, University Medical Center Groningen, Groningen, Netherlands, ⁵IdiSBa (Institut d'Investigació Sanitària Illes Balears), Palma de Mallorca, Spain, ⁶Laboratory of Cellular Therapy, Program of Cell Therapy and Immuno-Oncology, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁷Department of Medicine, University of Vermont, Burlington, VT, United States, ⁸Oncology Unit, University Hospital of Modena, University of Modena and Reggio Emilia, Modena, Italy

Idiopathic pulmonary fibrosis (IPF) is one of the most aggressive forms of idiopathic interstitial pneumonias, characterized by chronic and progressive fibrosis subverting the lung's architecture, pulmonary functional decline, progressive respiratory failure, and high mortality (median survival 3 years after diagnosis). Among the mechanisms associated with disease onset and progression, it has been hypothesized that IPF lungs might be affected either by a regenerative deficit of the alveolar epithelium or by a dysregulation of repair mechanisms in response to alveolar and vascular damage. This latter might be related to the progressive dysfunction and exhaustion of the resident stem cells together with a process of cellular and tissue senescence. The role of endogenous mesenchymal stromal/stem cells (MSCs) resident in the lung in the homeostasis of these mechanisms is still a matter of debate. Although endogenous MSCs may play a critical role in lung repair, they are also involved in cellular senescence and tissue ageing processes with loss of lung regenerative potential. In addition, MSCs have immunomodulatory properties and can secrete anti-fibrotic factors. Thus, MSCs obtained from other sources administered systemically or directly into the lung have been investigated for lung epithelial repair and have been explored as a potential therapy for the treatment of lung diseases including IPF. Given these multiple potential roles of MSCs, this review aims both at elucidating the role of resident lung MSCs in IPF pathogenesis and the role of administered MSCs from other sources for potential IPF therapies.

Keywords: cell based therapy, extracellular matrix, exosomes, idiopathic pulmonary fibrosis, mesenchymal stem cells

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrosing lung disease of unknown cause that occurs primarily in older adults with a median survival of 3 years after diagnosis. It is diagnosed by clinicopathological criteria, including (Raghu et al., 2011) the radiographic and/or histological hallmark pattern of usual interstitial pneumonia (UIP). Prognosis remains extremely poor with most patients dying from progressive respiratory failure, often precipitated by acute events, namely disease exacerbations (Collard et al., 2016). As a therapeutic strategy, the two antifibrotic drugs Pirfenidone and nintedanib can slow down the respiratory functional decline of IPF patients, and according both the real-world data and randomized controlled trials, such as CAPACITY and ASCEND improve survival in patients (Guenther et al., 2018; Jo et al., 2017). Despite that, IPF still has a high mortality rate and that survival times are quite heterogenous (Noble et al., 2011; Gaspole et al., 2014; Sgalla et al., 2016; Richeldi et al., 2017; Lederer and Martinez, 2018; Cerri et al., 2019).

The pathogenesis of IPF is complex and far from being fully understood (Ley et al., 2011; Ryu et al., 2014). Current hypotheses center on alveolar epithelial and vascular endothelial injuries that lead to fibroblast activation, abnormal matrix collagen deposition (King et al., 2011; Bellaye and Kolb, 2015; Bitterman, 2018), aberrant repair mechanisms, inflammation, and a regenerative deficit of the alveolar tissue (Noble et al., 2011; Betensley et al., 2016). According to more recent studies, the onset and progression of IPF is due to the aberrant damage and activation of alveolar epithelial cells (AECs) that lead to the secretion of profibrotic, coagulant, and inflammatory cytokines controlling the proliferation, activation and differentiation of fibroblasts into myofibroblasts and the consequent secretion and deposition of extracellular matrix (ECM) proteins (Selman and Pardo, 2020). These mechanisms translate into increased overall lung structural rigidity and thickening of the alveolar-capillary barrier with decline in alveolar gas exchange function. Since current evidence indicates epithelial cells as primers of disease and myofibroblasts as the key effectors in perpetrating fibrosis, recent investigations have focused on the cellular origin of the myofibroblasts including the potential role of resident mesenchymal progenitors as major source (Selman and Pardo, 2020). In particular, among myofibroblasts precursors, lung resident MSCs (LR-MSCs) have recently been gaining attention as to whether their aberrant behavior might be crucial in the fibrotic process (Agha et al., 2014; Enes et al., 2017; Cao et al., 2019). While research on resident lung MSCs as key protagonists in the pathogenesis of lung fibrosis is still emerging, there are many studies focusing on different roles of MSCs obtained from other sources outside of the lung namely their therapeutic potential given a range of immunomodulatory and anti-inflammatory properties (Uccelli et al., 2008; Mastroli et al., 2019). To this purpose, a large number of pre-clinical investigations demonstrated efficacy of systemically or intratracheally

administered MSCs obtained from bone marrow, adipose tissue, and other sources in a range of lung injury models. This has led to consideration and initial clinical investigations in IPF and other chronic lung diseases. (Weiss and Ortiz, 2013; Burgess and Irene, 2019). In parallel, a growing number of clinical investigations have been exploring systemic MSCs administration for the potential treatment of acute lung injury including the acute respiratory distress syndrome (ARDS) as well as most recently as potential treatment of COVID-19 respiratory failure (Golchin et al., 2020; Meng et al., 2020; Zumla et al., 2020). Although the mechanism of actions of MSCs in lung diseases have not yet been fully elucidated, and are likely to be different depending on the disease, the beneficial effects seem to be mainly dependent on paracrine mechanisms including release of bioactive molecules (soluble proteins, nucleic acids, lipids) and extracellular vesicles (EVs) (Kim et al., 2012; Chen et al., 2018; Cruz and Patricia, 2020; Harrell et al., 2019; Beer et al., 2017; Vizoso et al., 2017). In general, the EVs consists of exosomes, micro-vesicles (MVs), and apoptotic bodies that can be discriminated by their size and origin in the cells. Exosomes contain several molecules such as protein, lipids, mRNA, miRNA (Valadi et al., 2007), mitochondrial DNA (Guescini et al., 2010) and others non coding RNAs (Ferguson and Nguyen 2016). MSCs-derived exosomes have demonstrated immunoregulatory (Dabrowska et al., 2021), angiomodulatory (Lee et al., 2013; Alcayaguiramiranda et al., 2016) and anti-apoptotic effects that control tissue repair and regeneration (Vishnubhatla et al., 2014; Lou et al., 2017) in both tissue culture and animal models. This includes a growing literature in which MSCs-derived EVs can be as effective as the MSCs themselves in pre-clinical models of lung injuries (Cruz and Patricia, 2020; Harrell et al., 2019; Beer et al., 2017; Vizoso et al., 2017).

In this dualistic scenario, the aim of this review is to explore the updated evidence on the molecular mechanisms of IPF from the alveolar epithelium damage to fibrotic changes, highlighting the role of resident lung MSCs as emerging key cellular determinant in IPF onset and progression and providing an overview of the potential role of MSCs from different sources and their secretome in cell-based therapies for lung fibrosis.

KEY MOLECULAR MECHANISMS OF IDIOPATHIC PULMONARY FIBROSIS AS AN EPITHELIUM DRIVEN DISEASE

Nowadays IPF is described as an epithelium-driven disease characterized by aberrant functional epithelium due to aging and exposure to alveolar injuries in combination with compromised lung tissue regeneration, leading to abnormal repair with an imbalance between profibrotic and antifibrotic factors. Notably, this aberrant reparative mechanism leads to an increased fibroblast proliferation and myofibroblast activity

resulting in ECM deposition. It is known that the lung consists of quiescent tissue with little cell turnover at rest, compared for example to intestinal epithelial tissues. However, after injury it has the capability to efficiently regenerate the damage in both airway and alveolar niches (Beers and Morrissey, 2011). In normal lung, alveolar injuries are followed by depletion of type 1 alveolar epithelial cells (AECI) that are located at the interface with vascular endothelium and participate in alveolar gas exchange function. The lack of AECI is compensated by the alveolar epithelial cell 2 (AECII) that normally secrete the pulmonary surfactant to maintain the surface tension, but also have capacity to proliferate and differentiate into AECI, restoring the alveolar epithelium once injured (Fomby et al., 2010). The abnormal reparative response to injury of epithelial cells in IPF represents an initial and crucial mechanism of disease. The epithelial secretion of pro-fibrotic factors promotes fibroblast migration, proliferation, activation and differentiation into myofibroblasts with deposition of exaggerated ECM and subsequently distortion of the lung architecture. Several mechanisms and molecular pathways in lung IPF epithelium have been demonstrated to contribute to the development of the disease. Among these, abnormal AECII hyperplasia in response to injury results in the formation of mucus-filled microcystic structures that can evolve into macrocysts, compromising epithelial differentiation and alveolar epithelial cell function (Seibold et al., 2013; Vaughan et al., 2015). Indeed, in the damaged alveolar epithelium of IPF lungs the process named “bronchiolization” leads to migration of abnormal basal cells with accumulation of nuclear β -catenin (basal-cell hyperplasia) from adjacent bronchioles toward areas of alveolar injury colonizing them leading to aberrant re-epithelialization and contributing to disease progression. The integrity of the alveolar epithelium is severely disrupted in IPF lungs where abnormal epithelium covering the fibroblastic foci displayed a bronchiolar immunophenotype (Chilosi et al., 2003). Different works support the concept that bronchiolar abnormalities in IPF are due to changes in lung epithelial cell differentiation (Plantier et al., 2011). In particular, abnormal basal cells may differentiate into non-ciliated Club cells or ciliated FoxJ1 expressing bronchial cells, resulting in bronchiolization of damaged alveoli. Thus, bronchiolization of enlarged alveolar ducts, cysts and alveoli, results in the typical honeycombing that can be seen in the lung of IPF patients (Plantier et al., 2011).

Recently, it has been shown that the oncogene epithelial cell transforming sequence 2 (ECT2), a guanine nucleotide exchange factor (GEF) for Rho GTPases, is upregulated in hyperplastic AECII of IPF patients, and can contribute to the hyperplastic and proliferative lung epithelial cell phenotype (Ulke et al., 2019). In addition, pro-fibrotic mediators including transforming growth factor beta-1 (TGF- β 1), platelet-derived growth factor (PDGF), tumor necrosis factor (TNF), endothelin-1, connective tissue growth factor (CTGF), osteopontin, and CXC chemokine ligand 12 (CXCL12) (Pardo et al., 2005; Selman and Pardo, 2020) are up-regulated in AECs and can contribute to the

progression of fibrosis and aberrant extracellular matrix remodeling.

TGF β SIGNALING AND CROSS-TALK WITH WNT AND SONIC HEDGEHOG PATHWAYS ACTIVATED IN EPITHELIAL CELLS OF IDIOPATHIC PULMONARY FIBROSIS PATIENTS

TGF β can be considered a key regulator of fibrotic process favoring migration, proliferation, and activation of fibroblasts, differentiation into myofibroblasts, and deposition of ECM proteins (Meng et al., 2016; Horowitz and Thannickal, 2019). Indeed, TGF β receptor complex activation leads to downstream canonical (SMAD2 & 3) (Massagué, 2014) and non-canonical signaling cascades (PI3K, MEK, mTOR, etc) (Hu et al., 2018), which orchestrate the transcription of profibrotic mediators, growth factors, microRNAs, and ECM proteins (Andrianifahanana et al., 2013). Furthermore, cross-talks exists with TGF β 1 signaling and pathways overexpressed by epithelial cells of IPF patients such as Wnt and Sonic hedgehog (Shh) (Bolaños et al., 2012; Cigna et al., 2012). Zhou et al. (2012) found that TGF- β 1 and Wnt/ β -catenin crosstalk played a role in IPF pathogenesis since TGF- β 1 activate Wnt/ β -catenin pathway and together with Wnt/ β -catenin signaling induced epithelial-mesenchymal transition and myofibroblast activation (Zhou et al., 2012). Hasaneen et al.; found that TGF- β 1 triggered the release of a glycosylated transmembrane protein named EMMPRIN (Extracellular Matrix metalloproteinase Inducer) that increases the expression of some matrix metalloproteinase (MMP) and activates β -catenin/canonical Wnt signaling pathway. Here, EMMPRIN overexpression led to an anti-apoptotic and pro-fibrotic phenotype in lung fibroblasts of IPF patients (Hasaneen et al., 2016). Indeed, ICG-001, an inhibitor of T-cell factor (TCF)/ β -catenin transcription, has been shown to repress TGF β 1-induced EMT and reverse pulmonary fibrosis in mice (Henderson et al., 2010). More recently, it was demonstrated that chronic Wnt/ β -catenin activity in the IPF lung increased AECII senescence, leading to further progenitor cells dysfunction and impaired lung repair (Lehmann et al., 2020). In contrast, previous studies have shown that a particular lineage of Wnt responsive alveolar epithelial progenitor cells within the AECII population acted as a central player in lung regeneration after acute injury, being able to self-renew (Zacharias et al., 2018). Bolanos et al. (2012) found that Shh pathway is activated in IPF lungs and might contribute to IPF pathogenesis by increasing fibroblast proliferation, migration and ECM production. They measured the expression of Shh, Patched-1, Smoothed, and transcription factors glioma-associated oncogene homolog GLI1 and GLI2 in IPF and normal lungs finding that most of them were overexpressed in IPF (Bolanos et al., 2012). Further, TGF- β 1 modulates the expression of key components of the hedgehog pathway in lung fibroblasts, while the activity of the transcription factor GLI from the primary cilium is required to induce and maintain myofibroblast differentiation (Cigna et al., 2012).




FIGURE 1 | Different response from the epithelium to lung injury in normal and IPF lung. In normal lung, the depletion of alveolar epithelial cells 1 (AECI) that play a pivotal role in gas exchange with the adjacent blood vessels after injuries, is compensated/replenished by/upon the differentiation of alveolar epithelial cells 2 (AECII) in AECI, restoring the alveolar epithelium. In lung epithelium of IPF patients, the regeneration of AECI by AECII progenitors is compromised, leading to impaired alveolar re-epithelialization. Together with the aberrant repair mechanisms the AECs start to secrete pro-fibrotic mediators that through different molecular pathway and downstream effectors lead to fibroblast migration, proliferation, activation and differentiation into myofibroblasts with deposition of exaggerated ECM that drastically compromise the lung biomechanics properties.

Among other pathways involved, PDGF showed mitogenic and chemoattractant effects on fibroblasts while connective tissue growth factor (CTGF) was found to promote the progression of fibrosis either activating fibroblasts or through TGF-β pathway (Allen and Spiteri 2002).

TNF-α, OSTEOPONTIN, CXCL12, AND MATRIX METALLOPROTEASES INVOLVEMENT IN THE IDIOPATHIC PULMONARY FIBROSIS PATHOGENESIS

Tumor necrosis factor-alpha (TNF-α) was found to cause loss of fibroblast Thy-1 surface expression, thus contributing to myofibroblast differentiation (Kis et al., 2011). Selman and

Pardo reported that osteopontin acted on both neighboring epithelial cells and fibroblast to trigger a migratory and proliferative phenotype (Selman and Pardo, 2020). Recently CXCL12 was reported to act on CXCR4, which is expressed in advanced form of interstitial lung diseases, particularly when cystic lesions are present (Jaffar et al., 2020). Furthermore, matrix metalloproteases (MMPs) showed to play a role in the progression of IPF. Particularly, MMP1 and MMP7 are strongly expressed in the IPF epithelial cells compared to the epithelium in normal tissue. MMP1 increases cell proliferation and protects epithelial cells from apoptosis (Herrera et al., 2013), while MMP7 is involved in the fibrotic response upon osteopontin (Pardo et al., 2005). **Figure 1** summarizes the different pathways involved in alveolar epithelial response to lung injury in normal and IPF lung.

HIPPO PATHWAY IN THE LUNG FIBROSIS PROGRESSION

It has been reported that Yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) that belong to the Hippo pathway are aberrantly activated in lung fibrosis. In particular, YAP/TAZ that act as sensors of mechanical forces in cell microenvironment, are activated in fibroblasts of fibrotic lung due to ECM stiffness thus subjected to mechanical stretch, leading to the secretion of profibrotic mediators and ECM proteins (Noguchi et al., 2018; Marchioni et al., 2020). This feed-forward loop enhances the lung fibrosis progression. Indeed, in epithelial cells, YAP/TAZ are also activated with the disruption of cell polarity and increased ECM stiffness in fibrotic tissues (Noguchi et al., 2018). To this purpose, (Xu et al., 2016b) after performing single-cell RNA sequencing of epithelial cells from IPF patients (Xu et al. 2016), through Pathway analysis showed that the YAP/TAZ, TGF- β , Wnt, and PI3K signaling pathways were aberrantly activated in epithelial cells of IPF lung patients (Gokey et al., 2018). They suggested that YAP interacted with mTOR/PI3K/AKT signaling increasing the proliferation and migration of lung epithelial cells. Then, YAP/TAZ pathway contributes to the pathogenesis of IPF in lung fibroblasts and epithelial cells. Recently, Sun and collaborators have shown that Hippo/TAZ signaling also affects the regenerative capacity of AECII progenitors. TAZ also named WW Domain Containing Transcription Regulator 1(WWTR1) plays a crucial role in AECII to AECI differentiation and thus contribute to the maintenance of alveolar integrity after injury. Notably, conditional deletion of TAZ in AECII dramatically reduced AECI regeneration during recovery leading to exacerbated alveolar lesions and fibrosis in a bleomycin induced lung injury model. In addition, TAZ signaling can activate pro-fibrotic responses in fibroblasts (Sun et al., 2019).

Despite all these insights, the complete molecular mechanisms behind/underlying the differentiation of AECII in AECI after acute lung injury and how this is dysregulated in IPF are far from being fully understood.

CELLULAR SENESENCE, GENETIC AND ENVIRONMENTAL RISKS IN THE PATHOGENESIS OF IDIOPATHIC PULMONARY FIBROSIS

As described above, epithelial damage and activation can drive myofibroblasts proliferation and the release of pro-fibrotic factors. What causes initial epithelial damage during the onset of IPF is not fully understood. To date, an integral model of IPF pathogenesis has been proposed where the presence of rare or common gene variants (genetic), cellular senescence and epigenetic reprogramming, converge to the initiation and progression of the disease (Michalski and Schwartz, 2020; Selman and Pardo, 2020). Indeed, aging-associated alterations as mitochondrial dysfunction and altered proteostasis could promote epithelial and fibroblast senescence in IPF lungs through the loss of proteome

integrity and the shortening of telomeres (Mora et al., 2017; Lederer and Martinez, 2018). Cellular senescence leads to replicative arrest, apoptosis resistance, and the acquisition of a senescence-associated secretory phenotype (SASP), that involves the release of several inflammatory, growth-regulating and tissue-remodeling factors and could thus contribute to pro-fibrotic responses (Kirkland and Tchkonja, 2017). Hence, it has been shown that the epithelial cells from IPF lungs strongly expressed cellular senescence markers p16 and p21 together with an increased secretion of SASP factors as insulin growth factor binding proteins (Igfbp) 3, 4 and 7 and MMP 3, 12 and 14 (Lehmann et al., 2017). Then, cellular senescence, might lead both to exhaustion of stem/progenitor cell renewal (dysfunction) with loss of regenerative abilities and to the secretion of pro-inflammatory and matrix-remodeling cytokines, such as IL-6, TGF- β , and matrix metalloproteases related to SASP, thus perpetrating fibrosis (Pardo and Moisé s Selman, 2021). Some of the mechanisms that have been shown to induce AECII senescence as driver of IPF progression involve the overexpression of Wnt/ β -catenin signaling, DNA damage and telomere shortening (Mora et al., 2017). Recently, it has been demonstrated that loss of PTEN (phosphatase and tension homolog deleted on chromosome ten) triggers senescence in AECs through the activation of the protein kinase B (Akt) signaling pathway leading to a reduction of the autophagy. In particular, in a murine model of bleomycin induced AECs senescence, repression of Akt2 with the pharmacological inhibition of the Akt pathway (LY294002 and MK2206), resulted in ameliorating fibrotic lesions. The cellular senescence in IPF lungs was then found to be modulated by Akt/PTEN pathway (Qiu et al., 2019). Recently, Yao and collaborators have shown the transcriptomic features of cellular senescence characterizing the AECII isolated from IPF lung tissue. In particular, they showed how the conditional loss of Sin3a in adult mouse brought to p53-dependent cellular senescence of AECII, cell depletion, and spontaneous and progressive pulmonary fibrosis. The authors suggested that progressive fibrosis might be caused by senescence rather than loss of AECII and that targeting of p53 could block fibrogenesis (Yao et al., 2020). To this purpose, with the advanced technology of single-cell RNA-seq, Adams and collaborators identified a new population of IPF lung epithelial cells that was transcriptionally distinct from any epithelial cell type previously described in the lung, named aberrant basaloid cells, characterized by senescence-related genes including CDKN1A, CDKN2A, CCND1, CCND2, MDM2, and GDF15 (Adams et al., 2019). Besides the direct role of senescence of epithelial cells in the progression of IPF, it has been demonstrated that senescence of lung fibroblasts might decrease the AECII proliferation and promote migration in wound healing, affecting the re-epithelialization process after injury in IPF lung (Blokland et al., 2020). It has been widely demonstrated that genetic susceptibility together with the environmental risks play a pivotal role in disease initiation and progression in both sporadic and familial IPF. In this context, the most validated and strongest genetic risk factor for both familial and sporadic IPF, is represented by the single

nucleotide polymorphism rs35705950 in the promoter region of the mucin 5B (MUC5B) gene (Steele et al., 2011; Allen et al., 2017; Allen et al., 2020). Normally, together with mucin 5AC (MUC5AC), MUC5B plays a crucial role in the muco-ciliary clearance (MCC) that is essential for removing inhaled debris and pathogens in the normal lung homeostasis (Roy et al., 2013; Bonser and Erle 2017). *In vivo* studies have demonstrated that full-length murine MUC5B overexpression in AECII of two lines of C57BL/6 mice resulted in muco-ciliary clearance dysfunction thus worsening bleomycin-induced lung fibrosis (Hancock et al., 2018). Indeed, in genetically susceptible individuals bearing the rs35705950 SNP that cause MUC5B overexpression and impaired MCC, it might happen that exposure to inhaled pro-fibrotic particles could compromise the epithelial repair response to cell injury (Ley et al., 2017). Genome wide-association studies have revealed several common and rare variants associated with sporadic and familial IPF (Fingerlin et al., 2013; Allen et al., 2017; Allen et al., 2020; Dressen et al., 2018). To this purpose, the common genetic variants associated with IPF are represented by gene involved in the airway mucin production (MUC5B, MUC2), cell-cell adhesion (DSP, DPP9) playing a critical role in the maintenance of epithelial integrity, innate and adaptive immune response (Toll-Like receptor signaling, TOLLIP, TLR3), cytokine and growth factor signaling (IL1RN, IL8, IL4, TGF β 1), telomere maintenance (TERT, OBFC1) and cell cycle regulation (KIF15, MAD1L1, CDKN1A, TP53) (Michalski and Schwartz, 2020).

Rare variants of genes encoding proteins involved in telomere biology and maintenance have been identified in about 30% of patients with familial IPF whose AECII are characterized by short telomeres and proteins for surfactant production and secretion. These proteins include TERT, TERC (telomerase RNA component) TINF2 (TERF1 interacting nuclear factor 2), DKC1 (dyskerin), RTEL1, PARN (poly(A)-specific ribonuclease) and NAF1 (nuclear assembly factor 1 ribonucleoprotein) (Kropski et al., 2014; Kropski et al., 2015; Alder et al., 2015; Stuart et al., 2015; Stanley et al., 2016), SFPTA1, SFPTA2, SFPTC (surfactant protein A1, A2, C) and ABCA3 (ATP Binding Cassette Subfamily A Member 3) (Nureki et al., 2018; Doubková et al., 2019; Takezaki et al., 2019).

Finally, as mentioned above there are environmental risks such as cigarette smoke, inhalation of wood and metal dust, and other exposures that might contribute to the onset and progression of IPF, causing injury in the “genetically susceptible” patients (Barczyk et al., 2015; Phan et al., 2020; Shull et al., 2020). Indeed, the environmental risks might result in epigenomic modifications, with the alteration in key genes regulation contributing to the pathogenesis of IPF. To this purpose, exposure of cigarette smoke (CS) triggers DNA damage-related chromatin binding changes, and alterations in DNA methylation, influencing gene transcription and the downstream response of cells to injury (Vaz et al., 2017). Overall, however, the mechanisms and the correlation between environmental risk factors, genetic predisposition, aging and IPF pathogenesis need to be further elucidated.

THE EFFECT OF AGING ON MESENCHYMAL STROMAL/STEM CELLS

The cellular senescence of MSCs is a cellular mechanism that compromises their regenerative potential involving the oxidative state of the cell and mitochondrial dysfunction (Li Y et al., 2017). Despite lack of complete understanding of the molecular mechanisms and signaling pathways of senescence in MSCs, the senescence-associated phenotypes are characterized by an increase in the SA- β -gal activity, in the G1 cell cycle arrest, in the reactive oxygen species (ROS) production and expression of p53 and p21 (Jiang et al., 2008) and in a compromised autophagy process. One effect of MSCs aging can be seen in their decreased osteogenic activity. The molecular pathway behind the osteogenic activity is related to the expression of the transcription factor RUNX2/CBFA1 and the PI3K-AKT pathway that both decrease with age (Atashi et al., 2015). Additionally, it has been demonstrated that the adipogenic potential of MSCs tend to decline with aging and after different passages in *in vitro* culture mediated in part through the PPAR γ modulation, an adipogenic-specific transcription and cross-talk with Wnt/ β -catenin signaling pathway (Xu C et al., 2016).

Cellular senescence leads to replicative arrest, apoptosis resistance, and the acquisition of a senescence-associated secretory phenotype (SASP), that involves the release of several inflammatory, growth-regulating and tissue-remodeling factors and could thus contribute to pro-fibrotic responses (Kirkland and Tchkonja, 2017). Then, cellular senescence, might lead both to exhaustion of stem/progenitor cell renewal (dysfunction) with loss of regenerative abilities and to the secretion of pro-inflammatory and matrix-remodeling cytokines, such as IL-6, TGF- β , and matrix metalloproteases related to SASP, causing persistent fibrosis. (Pardo and Moisés Selman, 2021). Indeed, a crucial mechanism that leads to MSCs senescence is the oxidative stress that leads to the production of free radicals/ROS (reactive oxygen species) the majority of which are produced by the mitochondrial respiratory chain (Liu et al., 2020). From a molecular point of view the p38/MAPK axis triggers MSCs senescence through ROS production and accumulation initiating the oxidative process that can lead to mitochondrial dysfunction, DNA damage and protein damage. In the endoplasmic reticulum (ER) take place correct folding and assembling of the proteins into their native conformation prior to be transported to intracellular organelles or cell surface. In general, during the ER stress the correct protein folding is impaired and the unfolded or misfolded proteins accumulate in the ER lumen compromising the ER homeostasis. Then, the accumulation of aberrant folded proteins activates as a cellular protective mechanism, the unfolded protein response (UPR) ameliorating cell hemostasis and survival during ER stress process. (Schröder and Kaufman, 2005; Cao and Kaufman, 2012). Indeed, it has been demonstrated that accumulation of misfolded, or unfolded, proteins into the lumen of ER might contribute to the progression of age-related diseases (Powers et al., 2009; López-Otín et al.,). Then, the oxidative stress, with compromised mechanism of UPR, might cause aging in MSCs

affecting their cell functions and survival (Geissler et al., 2013; Wang et al., 2018). Recently, it has been demonstrated that a deficiency in the UPR lead to inactivation of ATF6, which can contribute to MSCs aging (Wang et al., 2018). In human MSCs, ATF6 is involved in cellular proteostasis, the process responsible for the preservation of a functional proteome and telomere shortening. The inactivation of ATF6 cause the accumulation of protein aggregates and compromise the integrity of various membrane organelles (Wang et al., 2018).

Indeed, these aging-associated alterations, including mitochondrial dysfunction and altered proteostasis, can also promote epithelial and fibroblast senescence in IPF lungs (Lederer and Martinez, 2018; Mora et al., 2017). Conceivable strategies to prevent aging in MSCs, for example genetic engineering through the knockdown of the tumor suppressor p16INK4a/CDKN2A (p16, cyclin-dependent kinase inhibitor 2A, CDKN2A) might lead to increase of proliferation rate and clonogenicity of MSCs (Gu et al., 2012). However, these might also increase the tumorigenesis risks. Finally, the use of growth factors such as exogenous FGF-2, PDGF and EGF have been demonstrated to reduce MSCs senescence and increase proliferation (Gharibi and Hughes, 2012). These might also be potential therapeutic interventions.

THE ROLE OF RESIDENT LUNG FIBROBLASTS AND BONE MARROW PROGENITOR CELLS IN PULMONARY FIBROSIS

Resident lung fibroblasts represent key effector cells in IPF pathogenesis since under the action of TGF- β can proliferate and differentiate into myofibroblasts promoting fibrogenesis and impairing normal alveolar epithelial repair in response to damage (David and Cory, 2017; Chanda et al., 2019). Here, the resident fibroblasts increase the synthesis of collagen and mesenchymal proteins, such as Vimentin and α -SMA with the activation of Wnt/ β -catenin axis favoring the progression of IPF (Shi et al., 2017). Then, myofibroblasts, expressing α -SMA, trigger ECM accumulation and deposition with an increase in the structural rigidity, decrease in contractility of lung tissue, and impaired support of alveolar repair (Zhang et al., 1996; Wu and Tang, 2021). According to recent studies, it has been shown that there are several populations of resident lung fibroblasts including fibroblasts localized in the lung interstitium adjacent to alveolar epithelial cells and lipofibroblasts, mainly characterized by neutral lipids, located adjacent to AECII. Lipofibroblasts are implicated in alveolar maturation and surfactant production as well as FGF10 secretion, and have been shown to modulate the epithelial stem-cell niche in adult mouse lungs (Alam et al., 2015; Agha et al., 2017). These lipofibroblasts are characterized by specific markers such as Sca-1, CD248 (Bartis et al., 2016) and PDGFR α (Iwayama et al., 2015; Wang et al., 2017). Particularly, PDGFR α allows the discrimination between interstitial resident fibroblasts and lipofibroblasts from pericytes, mesenchymal cells closely related

to vascular smooth muscle cells (VSMCs) that underlie and envelop capillaries, forming focal contacts with adjacent endothelial cells (Green et al., 2016). Recent studies of lineage tracing revealed that PDGFR α -expressing interstitial fibroblasts and/or lipofibroblasts can each differentiate into myofibroblasts after lung injury and that myofibroblast to lipofibroblast *trans*-differentiation is required for fibrosis attenuation in the mouse lung (El Agha et al., 2017).

As myofibroblasts represent key effector cells in lung fibrosis due to deposition of collagen and formation of scar tissue, their cellular origin and potential precursors have been extensively studied (Hinz et al., 2007; Fernandez and Oliver, 2012; Bochaton-Piallat et al., 2016; Horowitz and Thannickal, 2019). In this scenario, several population have been analyzed: 1) resident lung fibroblasts that under the influence of the profibrotic microenvironment directly differentiate into myofibroblasts (Phan 2002), 2) epithelial cells that lose their characteristic markers (such as E-cadherin and zona occludens-1) and acquire mesenchymal properties (such as fibroblast-specific protein-1 and α -SMA expression) in a process named epithelial-mesenchymal transition (EMT) (Willis et al., 2005; Kim et al., 2006) 3) bone marrow (BM)-derived cells as circulating fibrocytes (Phillips et al., 2004; Moore et al., 2005) and 4) pericytes (Scotton and Chambers, 2007; Wipff et al., 2007; Hinz, 2012; Hung et al., 2013). While more recent investigations have moved away from any significant roles of EMT or circulating fibrocytes as myofibroblast sources (Rock et al., 2011; Kleaveland et al., 2014; Barron et al., 2016; Chong et al., 2019), cell-lineage tracing experiments using reporter mouse models have focused attention on resident mesenchymal cell populations that can acquire myofibroblastic phenotype. These include:

- interstitial lung fibroblasts localized in the interstitium immediately adjacent to alveolar epithelial cells (Angeles, 2015; Barron et al., 2016),
- lipofibroblasts, that are lipid-droplet-containing interstitial fibroblasts located within close proximity to AECIIs (El Agha et al., 2017; Alam et al., 2015),
- pericytes localized within the capillary basement membrane connected to each other and with one or more endothelial cells (Marriott et al., 2014; Barron et al., 2016),
- mesothelial cells from pleural-mesothelium that line the visceral and parietal pleural surfaces (Karki et al., 2014), and
- resident lung mesenchymal progenitors (Xie et al., 2016), whose contribution in myofibroblast differentiating process seems prevalent.

Since the first isolation and characterization of LR-MSCs from human transplanted lungs, there has been increasing interest in their characterization with specific molecular markers for recognition, their exact location in the lung niche, their role in regulation of lung tissue homeostasis, and their role in the lung repair and regeneration after injury (Burgess and Irene, 2019; Sveiven and Nordgren, 2020). In particular, the expression of mesenchyme-specific t-box transcription factor (TBX4), that characterizes early mesenchyme progenitors during embryonic lung development, correlates with the activation and proliferation

of myofibroblast accumulation in lung fibrosis. Then, in the adult lung the TBX4 positive lineage are fibroblasts, smooth muscle cells, pericytes, and endothelial cells (Xie et al., 2016). Indeed, it has been shown that the numbers of LR-MSCs decreases during experimentally induced fibrosis in mice. This cell population has also been shown to express ATP-binding cassette sub-family G member 2 (ABCG2) (Jun et al., 2011) and lineage tracing experiments revealed that ABCG2+ cells are located in perivascular regions and in proximity of AECI in the mouse lung. In a bleomycin mouse model ABCG2+ cells are amplified and significantly transform into myofibroblasts, contributing to the progression of lung fibrosis (Marriott et al., 2014). Moreover, another GLI1 (glioma-associated oncogene homolog 1) positive perivascular lung resident MSCs population has been shown to contribute to myofibroblast formation in the bleomycin pulmonary fibrosis mouse model (Kramann et al., 2015). Recently in a bleomycin mouse model, Cao et al. showed that Wnt10a had a pivotal role in pulmonary fibrosis as they found an increased expression level of Wnt10a secreted by LR-MSCs undergoing myofibroblastic differentiation. Indeed, after isolation of LR-MSCs with myofibroblast characteristics from fibrotic lungs they found an increase in Shh pathway activity in these cells. They demonstrated that the Shh/glioblastoma (Gli) pathway was a key regulator of LR-MSCs-to-myofibroblast transition in pulmonary fibrosis. Finally, they showed that the suppression of the Shh-Wnt signaling prevented myofibroblast differentiation from LR-MSCs ameliorating pulmonary fibrotic lesions (Cao et al., 2019).

Furthermore, the role of lipofibroblasts and their contribution to the myofibroblast cell population in IPF lungs have been studied in recent works. Among them, in the study from Kheirollahi and colleagues they demonstrated that the antidiabetic drug, metformin, inhibits collagen production in primary human lung fibroblasts and in *ex vivo* cultured human IPF model and triggers the myo-to lipofibroblast transdifferentiation leading to a recovery from fibrosis. They further demonstrated that treatment of bleomycin-injured mice with metformin resulted in a resolution of fibrosis altering the fate of myofibroblasts and enhanced their lipogenic differentiation (Kheirollahi et al., 2019). Finally, they showed that the antidiabetic drug metformin had potent antifibrotic effects in the lung, through the inhibition of TGF β 1 signaling and collagen formation together with PPAR γ signaling activation and lipogenic differentiation.


In another study from Zysman and colleagues (Zysman et al., 2020); they investigated whether the cell-cycle inhibitor p16INK4a limits lung regeneration after newborn bronchopulmonary dysplasia (BPD), that lead to the arrest of alveolar development. They found that p16INK4a decrease leads to an increase of neutral lipid synthesis promoting lipofibroblast and AECII development within the lung stem-cell niche. Indeed, they found that treatment with a PPAR γ (peroxisome proliferator-activated receptor γ) agonist increased lipofibroblast and AECII, restoring alveolar architecture after hyperoxia-exposure in mice (Zysman et al., 2020). Thus, the “plasticity” of myofibroblasts that are able under proper conditions and treatment to transdifferentiate back into lipofibroblasts, that contribute to the progression of IPF,

provides the possibility to study novel drugs and compound to revert the fibrotic process in the lung niche.

To date, the emerging picture in the alveolar niche of IPF lung, indicates that there is a heterogenous myofibroblast population that may derive from different sources including interstitial lung fibroblasts, lipofibroblasts, pericytes, mesothelial cells and lung-resident MSCs rather than from EMT processes/epithelial or BM-derived cells (Figure 2).

THE ROLE OF LUNG RESIDENT MESENCHYMAL STROMAL/STEM CELLS IN LUNG HOMEOSTASIS, INJURY AND REPAIR

Adult resident stem cells are distributed in organ-specific niches which provide an appropriate microenvironment that regulates their development and functionality. Therefore, MSCs of all tissue origins have a common cellular signature even if there are also certain molecular features that seem to be organ-specific including the lung niche (Klein, 2020). In this regard, the characterization of human LR-MSCs meets the minimal suggested ISCT criteria for MSCs (Dominici et al., 2006) including expression of cell surface proteins as CD29, CD73, CD90, CD105 and CD146 (Kruk et al., 2021) besides being negative for hematopoietic markers. *In vitro* differentiation experiments have further demonstrated multilineage differentiation of LR-MSCs isolated from central and peripheral transbronchial biopsies, into adipocytes, osteoblasts and chondrocytes (Rolandsson et al., 2014). Nevertheless, it has been reported that LR-MSCs express higher level of FGFR2 as compared to BM-MSCs in mouse and rats. FGFR2 is bound by FGF10 leading to LR-MSCs activation and migration (Agha et al., 2014; Enes et al., 2017). To this purpose, Tong et al.; showed that in rats intratracheal administration of FGF-10 in lungs, led to LR-MSCs mobilization that allowed their collection through bronchoalveolar lavage. The collected LR-MSCs were cultured *in vitro* and then intratracheally delivered to rats after LPS-induced lung injury with more beneficial effects as compared to BM-MSCs used as positive control (Tong et al., 2016). Then, Sveiven and Nordgren in a recent review gave an update on both differences and similarities between BM-MSCs and LR-MSCs about the surface protein expression profile, the transcriptome, proteome and secretome (Sveiven and Nordgren, 2020). In particular, both the transcriptomic data and the pathway analysis of proteomic data showed that pathways involving Wnt, elasticity, motility, MET signaling, and integrins were more up-regulated in LR-MSCs as compared to BM-MSCs. Among the differences regarding the secretome, it has been shown that BM-MSCs secreted significantly less monocyte chemoattractant protein-1 (MCP-1, CCL2), crucial for macrophage recruitment, than LR-MSCs, while no significant differences in immunosuppressive effects on lymphocytes were observed between the two cell populations (Larsson et al., 2016). In another study comparing murine LR-MSCs and BM-MSCs in



an elastase-injury mouse model it was suggested that LR-MSCs displayed prolonged retention in the lungs upon intravenous administration, which might be attributed to the specific expression of adhesion molecules (Hoffman et al., 2011). In a similar elastase model, effects of murine LR-MSCs, BM-MSCs and adipose derived (AD)-MSCs were compared. All sources reduced alveolar epithelial and endothelial cell damage and neutrophil infiltration and increased elastic fiber content (Figure 2). In contrast to intravenous delivery, intratracheal MSCs administration further reduced alveolar hyperinflation and collagen fiber content, while AD-MSCs and LR-MSCs showed a more significant reduction in fractional area of alveolar collapse compared to BM-MSCs (Antunes et al., 2014). In 2012 Ricciardi et al.; showed that LR-MSCs do not significantly differ from human BM-MSCs with regards to the immunophenotype, stemness gene profile and mesodermal differentiation potential. Indeed, *in vitro* co-culture of either LR-MSCs and BM-MSCs with activated T cells or NK cells showed the same inhibitory effect of T-cell and NK cells proliferation from the two different cell lines. They found that lung-MSCs expressed higher basal level of the nestin marker; moreover *in vitro* treatment with retinoic acid showed that the LR-MSCs led to higher epithelial cell differentiation and polarization compared to BM-MSCs (Ricciardi et al., 2012). The authors evaluated the effect of retinoic acid treatment *in vitro* on LR-MSCs and BM-MSCs after 4 weeks of RA culture and through phase-contrast microscopy. While, both LR-MSCs and BM-MSCs showed a round-cuboid shape as epithelial cells at the end of the culture, LR-MSCs cultured with RA displayed a stronger phenotype. Further, after analyzing LR-MSCs by trans epithelial electric resistance (TEER) assay after RA treatment to measure and

quantify the formation of tight and adherence junctions it was found a higher polarization tendency in LR-MSCs compared to BM-MSCs (Ricciardi et al., 2012). Recently, LR-MSCs were isolated from allografts of human lung transplant recipients (Jarvinen et al., 2021). *In vitro* studies demonstrated that these LR-MSCs could suppress the proliferative capacity of T cells in response to a mitogenic or an allogeneic stimulus. The authors found that the immunosuppressive capacity of LR-MSCs was related to the secretion of PGE₂ since it was shown even in the absence of direct cell contact (Jarvinen et al., 2021).

Among studies aiming at characterizing the functional role of LR-MSCs, Kruk et al.: showed that human LR-MSCs can also be forced to differentiate *in vitro* toward adipocytes (Kruk et al., 2021), which closely resemble lipofibroblasts that support alveolar epithelial regeneration by secretion of FGF10 and assist in surfactant production. Thus, it might be speculated that such events, depending on cues from the microenvironment, may result in improved support of alveolar repair. *In vitro*, LR-MSCs secrete substantial levels of HFG as well as ECM molecules such as decorin, which is known to bind and inhibit TGF- β signaling (Kruk et al., 2021), acquiring of a role in alveolar repair. *In vitro* expanded LR-MSCs were also able to engraft decellularized lung tissue scaffolds and produce growth factors (Kruk et al., 2021). Concerning the role of LR-MSCs in lung pathologies and in particular in lung fibrosis several studies highlight a potential pathological role that is mediated by Wnt signaling. Cao et al. found that inhibition of the Shh-Wnt pathway in the bleomycin mouse model prevented LR-MSCs from differentiating into myofibroblasts and reduced lung fibrosis (Cao et al., 2018). Summers et al., further report in the same model that genetic

TABLE 1 | *In vitro* and *in vivo* studies involving LR-MSCs in lung homeostasis, injury and repair.

| Study | Method | Source of MSCs | Outcome |
|-------------------------|--|--|--|
| Tong et al. (2016) | Intratracheal administration to rat | LR-MSCs/BM-MSCs | ↓ inflammation after LPS-induced lung injury |
| Antunes et al. (2014) | Elastase murine model/intratracheal administration | LR/AD/BM-MSCs | ↓ alveolar hyperinflation ↓ Collagen fibers ↓ Alveolar area collapse |
| Ricciardi et al. (2012) | <i>In vitro</i> co-culture and RA treatment | LR-MSCs/BM-MSCs | ↓ T-cells/NK cells proliferation ↑ LR-MSCs polarization after RA treatment |
| Jarvinen et al. (2021) | <i>In vitro</i> studies | LR-MSCs/allograft of human lung transplant | ↓ T-cells proliferation ↑ immunosuppressive capacity-PGE ₂ secretion |
| Kruk et al. (2021) | <i>In vitro</i> studies-differentiation | LR-MSCs | ↑ HGF, ↑ ECM proteins (decorin), ↑ engraftment of decellularized lung tissue scaffold |
| Cao et al. (2019) | Inhibition of Shh/WNT signaling in bleomycin model | Analysis on murine LR-MSCs | ↓ myfibroblast differentiation of LR-MSCs ↓ lung fibrosis |
| Summers et al. (2020) | Knock out mouse model for MVPC | Murine MVPC-ABCG2 ⁺ cells | ↑ microvascular dysfunction ↑ lung fibrosis |
| Jun et al. (2011) | Intravenous injection of LR-MSCs | LR-MSCs | ↓ bleomycin-induced fibrosis ↓ arterial hypertension (PAH) |
| Marriott et al. (2014) | <i>In vitro</i> functional study/ <i>in vivo</i> study bleomycin mouse model | Human LR-MSCs/ ABCG2 ⁺ MSC | ↓ LR-MSCs cell number in IPF patients ↑ pro-fibrotic reprogramming |
| Martin et al. (2020) | <i>In vitro</i> studies | LR-MSCs from donor and IPF patients | ↓ decreased genetic profile in the ox-phospho. Pathway in LR_MSCs from IPF ↓ <i>in vitro</i> repair potential (lung epithelial wound) |


activation of Wnt in lineage labeled ABCG2 positive pulmonary mesenchymal vascular progenitor cells (MVPC) drive microvascular dysfunction and exacerbated fibrosis (Summers et al., 2021). In 2011 Jun and collaborators demonstrated that treatment of mice with bleomycin led to the decrease of endogenous LR-MSCs population identified as H33342^{low}CD45^{neg} by flow cytometry and *in vivo* by immunostaining to detect the multidrug resistance transporter ATP binding cassette (ABCG2). Indeed, they hypothesized that decrease in the LR-MSCs population favored the progression of fibrosis measured with Ashcroft score inflammation, and pulmonary arterial hypertension (PAH). The replacement of lung resident stem cells by intravenous injection of exogenous LR-MSCs immediately after the intratracheal administration of bleomycin reduced both the bleomycin-associated fibrosis and the PAH (Jun et al., 2011). The study from Marriott et al.; described the functional role of LR-MSCs in IPF. They found that LR-MSCs were located in the distal lung and expresses ABCG2 contributing to the myofibroblast population and lung tissue remodeling in IPF. They found that in patients with IPF or ILD ABCG2^{pos} cell numbers were decreased relative to control, possibly because most of them differentiated into myofibroblasts contributing to the lung remodeling during IPF (Marriott et al., 2014). In another functional study, Martin et al. compared LR-MSCs from donor and IPF patients and found that IPF derived LR-MSCs presented a decreased genetic profile in the oxidative phosphorylation pathway and had reduced potential to induce the repair of a lung epithelial wound in an *in vitro* indirect co-culture system (Martin et al., 2020). Thus, abnormalities in endogenous LR-MSCs may contribute to aberrant alveolar repair responses in IPF. For their use in autologous cell-based therapies, more insight into LR-MSCs function and potential abnormalities in IPF is crucial and may guide pre-conditioning strategies of LR-MSCs.

Finally, in addition to their molecular and functional properties, understanding the spatial location of LR-MSCs within the lung is crucial in order to elucidate their physiological role in maintaining lung homeostasis. Although the exact location of LR-MSCs remains under debate, recent studies found that human LR-MSCs express the so called “HOX code” characteristic of vascular wall MSCs (VW-MSCs derived from the vascular wall of adult human blood vessels) therefore pointing at a vascular nature. According to this picture, LR-MSCs would be located within two areas: 1. a vascular niche situated at the perivascular space between the vessels and the surrounding tissue, and 2. an alveolar niche in close contact with the capillary endothelial cells and the alveolar epithelial cells (Steens et al., 2021).

To date, given the poor functional characterization of LR-MSCs related to the bone marrow counterpart, their role in the lung homeostasis and pathologies should be inferred both from the studies published on LR-MSCs (Steens et al., 2021), and essentially from studies based on the comparison of those to BM-MSCs. Indeed, a deeper characterization of LR-MSCs, with more *in vitro* and *in vivo* studies that will recapitulate both the spatial location and the functional effects of these cells in the lung would clarify their role within lung tissue microenvironment to enrich the knowledge in the LR-MSCs biology in order to perform new and effective LR-MSCs-based therapy. (Table 1).

THE ROLE OF EXOGENOUSLY ADMINISTERED MESENCHYMAL STROMAL/STEM CELLS IN LUNG REPAIR AFTER INJURY

MSCs are able to regulate the adaptive and innate immune systems by either their paracrine effect via soluble factors or



by cell–cell contact mechanisms with inhibition of T-lymphocyte proliferation, modulation of regulatory T-cells (Tregs) function, maturation of dendritic cells, reduction of B-cell activation and proliferation, inhibition of proliferation and cytotoxicity of NK cells, and stimulation of regulatory T cells (Gharibi and Hughes, 2012; Gao et al., 2016). The paracrine effect of different sources of MSCs is expressed through the secretion of soluble anti-inflammatory factors including but not limited to TGF- β , hepatocyte growth factor (HGF), interleukin (IL)-10, IL-1 receptor antagonist (IL-1Ra) prostaglandin E2 (PGE2) microRNAs (Vishnubhatla et al., 2014; Gazdic et al., 2015; Maguire, 2013), and factors that drive endothelial and epithelial repair and regeneration such as angiopoietin 1 (ANGPT1), FGFs (FGF2, FGF10) keratinocyte growth factor (KGF)/FGF7, hepatocyte growth factor (HGF), epidermal growth factor (EGF) and vascular endothelial growth factor alpha (VEGFA). In addition, MSCs can modulate repair responses by the deposition and remodeling of extracellular matrix (Kruk et al., 2021) providing cues to instruct cellular behavior such as survival, migration and proliferation (Figure 3). There have been a wide range of MSCs anti-inflammatory and immunomodulatory properties demonstrated in preclinical models of lung injuries including pulmonary fibrosis (Behnke et al., 2020). Although BM-derived MSCs are the most extensively investigated (Zhang et al., 2019), MSCs from other sources such as umbilical cord, placenta and adipose tissue have been studied (Aguilar et al., 2009; Yamada

et al., 2004) (Table 2). As one example, in a bleomycin-induced lung injury model in mice, Moodley et al.; demonstrated that umbilical cord derived MSCs (uMSCs) can reduce lung inflammation and prevent fibrosis by up-regulating anti-inflammatory modulators and downregulating both cytokine production and pro-fibrotic factor release as measured through quantitative real-time PCR from whole lung suspensions from mice at 14 days post-bleomycin (Moodley et al., 2009). Indeed, in another study using the bleomycin mouse model of lung fibrosis, placenta-derived MSCs suppressed the infiltration of neutrophils, mitigated the inflammatory response and promoted lung tissue regeneration (Cargnoni et al., 2009; Antoniou et al., 2018). However, as shown in Table 2, in most of the preclinical studies, MSCs were administered after a few hours or days following the induction of lung damage and prevented the development of fibrotic changes (Jenkins et al., 2017). In contrast, when MSCs were administered at weeks 8, 10, 12, and 14 after-BLM induction (Moeller et al., 2008), no effect on lung collagen content was found while only improvement in Ashcroft score and lung TGF- β levels was reported. These studies mirror findings in one of the original studies on MSCs effects in the bleomycin lung model in which MSCs administration immediately after bleomycin significantly reduces inflammation, collagen deposition, and MMPs activation preventing development of fibrosis whereas delayed application decreased the inflammation but failed to reduce lung fibrosis (Ortiz et al., 2003). In another pre-clinical study Yu et al.;

TABLE 2 | Pre-clinical applications of MSCs in lung diseases. DAB = days after bleomycin administration.

| Study | Lung disease model | Type of MSCs | Source of MSCs | Effect | Timing of administration |
|------------------------|--------------------------|-------------------|---------------------|---|---|
| Li et al. (2017a) | Pulmonary fibrosis | Human fpMSCs | Placenta | ↓ collagen deposition, ↑ pro-fibrotic cytokines | 1 × 10 ⁵ cells-tail vein-3DAB |
| Cargnoni et al. (2009) | Pulmonary fibrosis | Murine/human MSCs | Placenta | ↓ neutrophil infiltration | 1–4X10 ⁵ cells - intraper.intrajug.intratrach.-15mAB |
| Moodley et al. (2009) | ARDS | Human MSCs | Umbilical cord | ↓ TIMP expression, ↓ lung cytokine, ↑ MMP expression | 1 × 10 ⁶ cells-tail vein-1DAB |
| Jun et al. (2011) | Pulmonary fibrosis | Murine MSCs | Lung | ↓ lymphocyte and granulocyte infiltration, ↓ PAH | 1.5–2.5 × 10 ⁶ -tail vein-14DAB |
| Moodley et al. (2013) | COPD- pulmonary fibrosis | Murine/human MSCs | Bone marrow, amnion | ↓ TGF-β, ↑ MMP-9, ↑ GM-CSF, ↑ IL-1RA | 1 × 10 ⁶ cells-tail vein-3DAB |
| Huleihel et al. (2017) | Pulmonary fibrosis | Human MSCs | Bone marrow | ↓ collagen deposition and CD45-positive cells | 5 × 10 ⁵ cells-tail vein-7DAB |
| Ortiz et al. (2003) | IPF | Murine MSCs | Bone marrow | ↓ collagen deposition, ↓ inflammation | 5 × 10 ⁵ cells-intrajug. 0-7DAB |
| Ortiz et al. (2007) | ILD | Murine MSCs | Bone marrow | ↓ IL-1 and TNF-α | 5 × 10 ⁵ cells-intrajug-0DAB |
| Huang et al. (2015) | Pulmonary fibrosis | Rat MSCs | Bone marrow | ↓ oxidative stress and collagen deposition | 2,5 × 10 ⁶ cells-tail vein -0-7DAB |
| Lee et al. (2014) | ALI | Murine MSCs | Bone marrow | ↓ TGF-β, ↓ IL-1β, ↓ VEGF, ↓ TNF-α, ↓ IL-6, ↓ NOS | 1 × 10 ⁷ -tail vein-4DAB |
| Ono et al. (2015) | IPF | Human MSCs | Bone marrow | ↓ endoplasmic reticulum stress, ↓ oxidative stress, ↓ TGF-β1 | 5 × 10 ⁵ cells-tail vein-0-1DAB |
| Lan et al. (2015) | IPF | Murine MSCs | Bone marrow | ↓ inflammation, ↑ lung function | 5 × 10 ⁵ cells-intratrach-0-3DAB |
| Cahill et al. (2016) | IPF | Murine MSCs | Bone marrow | ↓ IL-1β, ↓ apoptosis, ↑ HGF | 5 × 10 ⁴ cells-tail vein-6h-9DAB |
| Kotani T et al. (2017) | IP | Murine ADSCs | Adipose tissue | ↓ inflammation, ↓ fibrosis | 2,5 × 10 ⁴ cells-tail vein-0-7DAB |
| Lee et al. (2014) | IPF | Human ADSCs | Adipose tissue | ↓ fibrosis, ↓ apoptosis, ↓ TGF-β, ↓ epithelial cell hyperplasia | 3 × 10 ⁵ cells-intraper. 0-DAB |
| Tashiro et al. (2015) | IPF | Murine ADSCs | Adipose tissue | ↓ oxidative stress, ↓ fibrosis, ↓ apoptosis, ↓ TGF-β, ↓ MMP-2 | 5 × 10 ⁵ cells-tail vein-1DAB |
| Yu et al. (2015) | IPF | Murine MSCs | Bone marrow | ↑ lung injury repair, ↓ fibrosis, ↓ INFγ, ↓ MMP-1, ↓ TGF-β, ↓ MMP-9 | 2.5 × 10 ⁶ cells-tail vein-1,3,6DAB |
| Rubio et al. (2017) | IPF | Murine MSCs | Adipose tissue | ↓ lung and skin fibrosis, ↓ miR-199-3p, ↑ CAV-1 | 5 × 10 ⁵ cells-tail vein-1DAB |

further investigated the mechanism and timing of MSCs administration in bleomycin-induced pulmonary fibrosis. They demonstrated that BM-MSCs administration at day 3 and day 6 decreased lung fibrosis and inflammation down-regulating MMP9, TIMP-1, INF-γ and TGF-β to the same extent as after day 1 of bleomycin treatment. Thus, they stated that delayed BM-MSCs administration for up to 6 days after bleomycin treatment might be effective but did not look at longer intervals (Yu et al., 2015). Ni et al. demonstrated that in a humanized mouse model of BLM-induced lung fibrosis, human BM-MSCs administered at day 2 after bleomycin injection could prevent the progression of pulmonary fibrosis suppressing bleomycin-induced human T-cell infiltration and pro-inflammatory cytokine production targeting the PD-1/programmed death-ligand 1 pathway. However, BM-MSCs administration at day 7 after BLM injection did not improve lung function nor reverse established fibrosis. The authors concluded that human BM-MSCs administration displayed anti-fibrotic effects only in the early phase of BLM induced lung damage, namely the inflammatory phase (Ni et al., 2018). Taken together, these studies demonstrate that while MSCs are effective in mitigating acute lung inflammation and preventing

development of lung fibrosis, they do not reverse established fibrosis. As IPF is usually diagnosed only after extensive fibrotic changes are present, this raises questions as to whether MSCs administration will be beneficial in IPF. However, in a recent study from Zakaria et al. in albino rats BM-MSCs systemically administered 28 days after bleomycin-induction of lung damage; resulted in reversion of established fibrosis, restored lung architecture, and improved lung functions (Zakaria et al., 2021). The mechanisms by which these effects occurred need further study and may open up better understanding that will support use of systemically administered MSCs in IPF.

To date, the immunomodulatory effects of systemic or intratracheal administration of allogeneic and also xenogeneic MSCs on both the innate and adaptive immune response have been intensively explored (Masterson et al., 2019). In contrast, less is known about the interaction of lung resident MSCs with the immune system and role of LR-MSCs in pathogenesis or repair from lung injuries.

Finally, along with the beneficial role of exogenous MSCs administration, there are studies using gene therapy to improve the MSCs potency for the resolution of lung injury in different animal models. To this purpose, overexpressing of MSCs with

HGF (HGF-MSCs) which is a growth factor with anti-inflammatory, antiapoptotic, and reparative properties, have also been tested in acute lung injury models. To this purpose, MSC-based hepatocyte growth factor (HGF) has been used as gene therapy for RILI (radiation-induced lung injury). Mice receiving single dose radiation with 20 Gy of γ rays locally to the lung and HGF-modified MSCs (MSCs-HGF) revealed improved histopathological and biochemical markers of lung injury. MSCs-HGF reduced secretion and expression of proinflammatory cytokines, such as TNF- α , interferon- γ , interleukin (IL)-6, and intercellular adhesion molecule-1, increasing the expression level of anti-inflammatory cytokine IL-10 and decreasing the expression levels of profibrotic factors TGF- β , Col1a1 and Col3a1 culminating in the reduction of lung fibrosis progression (Wang et al., 2013). In another study from Chen and collaborators, rat bone marrow-derived MSCs transfected to express HGF increased MSCs viability, and inhibit the proinflammatory phenotype of MSCs in the inflammatory condition. In the rat model of ischemia/reperfusion I/R-induced lung injury, MSCs-HGF administration enhanced PaO₂ level and ameliorate lung pathological injury, compared with MSCs treatment (Chen et al., 2017).

PRE-CLINICAL STUDIES INVOLVING EXTRACELLULAR VESICLES DERIVED MESENCHYMAL STROMAL/STEM CELLS IN LUNG FIBROSIS

Given their ability to reduce inflammation and their action on myofibroblast activity, MSC-derived secretome and EVs have been increasingly investigated for development of new therapeutic strategies for lung fibrosis (Worthington and Hagood, 2020). In bleomycin-induced fibrosis in immunocompetent CD1 mice, lung spheroid cell-secretome (LSC-Sec) and exosomes (LSC-Exo) derived from human LSCs generated from whole lung samples were administered by inhalation to treat fibrosis progression. Starting at day 10 mice received daily nebulized inhalations for seven consecutive days with a dose of 10 mg of secretome protein per kg of body weight or 10×10^9 exosomes particles per kg of body weight or an equal volume of PBS (Dinh et al., 2020). The results demonstrated that both LSC-Sec and LSC-Exo treatments could attenuate and resolve bleomycin-induced lung fibrosis, restoring normal alveolar structure and decreasing both collagen accumulation and myofibroblast proliferation. Indeed, they showed that LSC-Exo reproduced part of the regenerative potency of the full secretome, while LSC-Exo overcame MSC-Exo in resolving pulmonary fibrosis and healthy lung function (Dinh et al., 2020).

Shentu and co-workers demonstrated in *in vitro* studies that MSC-derived EVs can play an antifibrotic role demonstrating down-regulation of TGF- β induced differentiation of isolated lung fibroblasts into myofibroblast, interaction with resident myofibroblasts through Thy 1, and delivery of miRNAs targeting profibrotic genes. To this purpose, MSC-EVs bearing

miR-630, a powerful suppressor of pro-fibrotic genes in lung fibroblasts, was used to reduce α -SMA expression in lung fibroblasts (Shentu et al., 2017; Fujita et al., 2018). Mansouri and collaborators demonstrated that human BM-MSCs-derived exosomes prevented and reverted experimental pulmonary fibrosis along with the modulation of monocyte phenotypes in bleomycin mice model (Mansouri et al., 2019). In particular, they initially evaluated the preventive effect of a single dose of human BM-derived MSCs (Mex) administered concurrently with endotracheal administration of bleomycin in 14-week-old mice on day 0. The results demonstrated that at day 7, Mex administration significantly reduced the bleomycin-induced pulmonary fibrosis and restored collagen content to levels similar to their bleomycin untreated-counterparts. In parallel studies, Mex administration at either day 7 or on day 21 decreased collagen content compared to control animals, although the administration after 21 days was not able to decrease the Ashcroft score (Mansouri et al., 2019). Since it is known that in lung diseases LR-MSCs can migrate from their tissue niche toward the alveolar space and can be recovered from the BAL fluid, LR-MSCs EVs have been isolated from BAL fluid (Sinclair et al., 2016; Shah et al., 2019). To this purpose, Martin-Medina et al.; isolated EVs from BALF collected from mice 14 days after intratracheal bleomycin, IPF patients, non IPF ILD patients, non ILD patients where BALF was performed for diagnostic evaluation (unclear cough) and ILD was excluded, and healthy volunteers as controls. The EVs were then characterized by transmission electron microscopy, nanoparticle tracking analysis, and Western blotting which demonstrated increased number of exosomes, according to their size distribution, in BALF from experimental lung fibrosis (bleomycin mouse model) and from patients with IPF compared to patients with non-ILD/non-IPF ILD. Notably, EVs from IPF BALF stimulated Wnt5A-mediated proliferation of primary human lung fibroblasts in *in vitro* studies (Martin-Medina et al., 2018).

CLINICAL STUDIES INVOLVING MESENCHYMAL STROMAL/STEM CELLS IN LUNG FIBROSIS

Clinical studies of MSCs administration in IPF patients to date have mainly consisted of small phase I safety investigations. MSCs are known to express major histocompatibility complex I (MHC I) and lack MHC II expression, a mechanism that allows them to escape immune host reaction. However, when MSCs are systemically infused, the high level of procoagulant tissue factor (TF) expressed might trigger the instant blood-mediated inflammatory reaction (IBMIR) with potential lethal consequences for patients. Thus, it has become crucial to find strategies aiming at modulating MSCs hemocompatibility in order to increase safety and efficacy of intravascular MSCs therapies (Moll et al., 2019). Focusing on IPF, the first phase I trial performed by Tzouveleakis et al.; showed safety of MSCs

application. This was a phase Ib, non-randomized, open label clinical trial to study the safety of three endobronchial infusions of autologous adipose derived stromal cells (ADSCs)-stromal vascular fraction (SVF) in patients with IPF ($n = 14$) of mild to moderate disease severity. They showed an acceptable safety profile with attributable serious short and long-term adverse events in all patients. However, there was no apparent suggestion of efficacy and the study was not designed to detect efficacy (Tzouveleakis et al., 2013). Another phase I safety clinical trial (AETHER) utilized a single intravenous infusion of allogeneic BM-MSCs in nine patients with mild to moderate IPF. No serious adverse events as death, pulmonary embolism, stroke and hospitalization for worsening dyspnea were observed through 60 weeks although two deaths occurred because of progression of IPF. Secondary exploratory end points demonstrated a decline in % predicted FVC and DLCO below the defined thresholds for IPF disease progression, however, this non-controlled trial was not designed to evaluate changes in lung function (Glassberg et al., 2017). However, as the pre-clinical data, to date, more strongly suggests a potential beneficial role of MSCs administration in reducing inflammation and preventing development of fibrosis rather than reversing established fibrosis, it would be informative to explore the effect of MSCs administration in an acute exacerbation of IPF for instance following a respiratory virus infection. However, to the best of our knowledge there are not as yet pre-clinical studies based on the induction of experimental respiratory virus infection in mice with bleomycin-induced fibrosis treated with administered MSCs.

CONCLUSION AND FUTURE PERSPECTIVE

There are multiple potential roles of MSCs in lung fibrosis. On one hand, given the lessons learned from preclinical studies, further strategies can be developed in which exogenously administered MSCs might contribute to prevent disease progression or might even revert established lung fibrosis, suppressing inflammation and supporting alveolar repair. This will involve further clarification on the route and timing of MSCs administration, source and age of MSCs administered and other factors that have thus far given rise to the heterogeneous results of available preclinical data. On the other hand, lung resident MSCs might contribute to IPF pathogenesis and progression as they might differentiate into

myofibroblast following lung damage. Moreover, whereas the role of LR-MSCs in lung fibrosis pathology is still being elucidated, it remains presently unknown whether healthy LR-MSCs could potentially restore/rescue this function. Since the microenvironment to which MSCs are exposed seems to regulate function and to affect further cellular development, it is arguable that healthy LR-MSCs might have a therapeutical effect in terms of lung regeneration. Thus, further work on characterizing MSCs from different sources, including LR-MSCs, in terms of function, phenotype and secretome will contribute to a greater understanding of the mechanism of disease in the aim of developing specialized and targeted approaches to treat lung fibrosis. Furthermore, besides the characterization of different MSCs sources, the gene therapy based on a deeper knowledge of molecular scenario of MSCs after their administration, would improve their potency and potentiate their effect to treat specific disease.

AUTHOR CONTRIBUTIONS

AS and RT equally contributed to the conception, design, writing, and editing of the manuscript and they should be considered both first author. IH and AM (4th author) wrote and critically edited the manuscript. AM (5th author), GB, IC, DA and FG reviewed the literature, designed the review, wrote the manuscript, and produced figures. LM, AM (11th author), SC, RF, LT, CN and IM wrote the manuscript and produced figures. DW, MD and EC critically reviewed and edited the manuscript. All the authors read and approved the final version of the manuscript.

FUNDING

Manuscript has been produced within the research program at Experimental Pneumology, University of Modena and Reggio Emilia (www.experimentalpneumology.unimore.it) with Dipartimenti Eccellenti Fundings (Miur 2017).

ACKNOWLEDGMENTS

We thank FIMARP (Federazione Italiana Malattie Rare del Polmone), Modena Golf Country Club, and AMMI (Associazione Mogli di Medici Italiani) for their support to our research.

REFERENCES

- Adams, T. S., Schupp, J. C., Poli, S., Ayoub, E. A., Neumark, N., Ahangari, F., et al. (2019). *Single Cell RNA-Seq Reveals Ectopic and Aberrant Lung Resident Cell Populations in Idiopathic Pulmonary Fibrosis*. bioRxiv. doi:10.1101/759902
- Agha, E. E., Herold, S., Alam, D. A. L., Quantius, J., Mackenzie, B., Carraro, G., et al. (2014). *Fgf10-positive Cells Represent a Progenitor Cell Population during Lung Development and Postnatally*, 296–306. doi:10.1242/dev.099747
- Agha, E. E. L., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., Kwapiszewska, G., et al. (2017). *Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis*. *Cell Stem Cell* 20 (2), 261–273.e3. doi:10.1016/j.stem.2016.10.004
- Aguilar, S., Chris, J. S., Katrina, M., Emma, N., Gordon, S., Geoff, L., et al. (2009). *Bone Marrow Stem Cells Expressing Keratinocyte Growth Factor via an Inducible Lentivirus Protects against Bleomycin-Induced Pulmonary Fibrosis*. *PLoS ONE* 4 (11), e8013. doi:10.1371/journal.pone.0008013

- Alam, D. A. L., El Agha, E., Sakurai, R., Kheirollahi, V., Moiseenko, A., Danopoulos, S., et al. (2015). Evidence for the Involvement of Fibroblast Growth Factor 10 in Lipofibroblast Formation during Embryonic Lung Development. *NIH 142*, 4139–4150. doi:10.1242/dev.109173
- Alcayaga-miranda, F., González, P. L., Lopez-verrilli, A., Aguila-díaz, C., Contreras, L., and Maroun Khoury, S. D. (2016). Prostate Tumor-Induced Angiogenesis Is Blocked by Exosomes Derived from Menstrual Stem Cells through the Inhibition of Reactive Oxygen. *species 7* (28), 44462–44477. doi:10.18632/oncotarget.9852
- Alder, J. K., Stanley, S. E., Wagner, C. L., and Hamilton, M. (2015). Exome Sequencing Identifies Mutant TINF2 in a Family with Pulmonary Fibrosis. *CHEST 147* (5), 1361–1368. doi:10.1378/chest.14-1947
- Allen, J. T., and Spiteri, M. A. (2002). Growth Factors in Idiopathic Pulmonary Fibrosis: Relative Roles. *Respir. Res. 3* (1), 13. doi:10.1186/rr162
- Allen, R. J., Guillen-Guio, B., Oldham, J. M., Ma, S. F., Amy, D., Paynton, M. L., et al. (2020). Genome-wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med. 201* (5), 564–574. doi:10.1164/rccm.201905-1017OC
- Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., et al. (2017). Genetic Variants Associated with Susceptibility to Idiopathic Pulmonary Fibrosis in People of European Ancestry: a Genome-wide Association Study. *Lancet Respir. Med. 5* (11), 869–880. doi:10.1016/S2213-2600(17)30387-9
- Andrianifahanana, M., Wilkes, M. C., Gupta, S. K., Rahimi, R. A., Repellin, C. E., Edens, M., et al. (2013). Profibrotic TGF β Responses Require the Cooperative Action of PDGF and ErbB Receptor Tyrosine Kinases. *FASEB J. 27* (11), 4444–4454. doi:10.1096/fj.12-224907
- Angeles, L. (2015). TISSUE-SPECIFIC STEM CELLS Progenitors of Secondary Crest Myofibroblasts Are Developmentally Committed in Early Lung. *Stem Cells 33* (3), 999–1012. doi:10.1002/stem.1911
- Antoniou, K. M., Karagiannis, K., Tsitoura, E., Bibaki, E., Lasithiotaki, I., Prokrou, A., et al. (2018). Clinical Applications of Mesenchymal Stem Cells in Chronic Lung Diseases (Review). *Biomed. Rep. 8* (4), 314–318. doi:10.3892/br.2018.1067
- Antunes, M. A., Laffey, J. G., Pelosi, P., and Patricia, R. M. (2014). Mesenchymal Stem Cells Trials for Pulmonary Disease. *J. Cel Biochem 115* (6), 1023–1032. doi:10.1002/jcb.24783
- Atashi, F., Modarressi, A., and Pepper, M. S. (2015). The Role of Reactive Oxygen Species in Mesenchymal Stem Cell Adipogenic and Osteogenic Differentiation: a Review. *Stem Cell Dev 24* (10), 1150–1163. doi:10.1089/scd.2014.0484
- Barczyk, M., Matthias, S., and Sabrina, M. (2015). Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis. *Stem Cell Rev. 11* (4), 598–620. doi:10.1007/s12015-015-9587-7
- Barron, L., Gharib, S. A., and Duffield, J. S. (2016). Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. *Am. J. Pathol. 186* (10), 2519–2531. doi:10.1016/j.ajpath.2016.07.004
- Bartis, D., Louise, E. C., Vijay, K. D., Lee, B., Fisher, A. J., Croft, A. P., et al. (2016). Role of CD248 as a Potential Severity Marker in Idiopathic Pulmonary Fibrosis. *BMC Pulm. Med. 16* (1), 1–10. doi:10.1186/s12890-016-0211-7
- Beer, L., Mildner, M., and Jan Ankersmit, H. (2017). Cell Secretome Based Drug Substances in Regenerative Medicine: when Regulatory Affairs Meet Basic Science. *Ann. Transl Med. 5* (7), 5–7. doi:10.21037/atm.2017.03.50
- Beers, M. F., and Morrissey, E. E. (2011). Science in Medicine The Three R's of Lung Health and Disease: Repair, Remodeling, and Regeneration. *J. Clin. Invest. 121* (6), 2065–2073. doi:10.1172/JCI45961.respiratory
- Behnke, J., Kremer, S., Shahzad, T., Chao, C., Böttcher-Friebertshäuser, E., Morty, R. E., et al. (2020). MSC Based Therapies—New Perspectives for the Injured Lung. *J. Clin. Med. 9* (3), 682. doi:10.3390/jcm9030682
- Bellaye, P. S., and Kolb, M. (2015). Why Do Patients Get Idiopathic Pulmonary Fibrosis? Current Concepts in the Pathogenesis of Pulmonary Fibrosis. *BMC Med. 13* (1), 1–3. doi:10.1186/s12916-015-0412-6
- Betensley, A., Sharif, R., and Karamichos, D. (2016). A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. *J. Clin. Med. 6* (1), 2. doi:10.3390/jcm6010002
- Bitterman, P. (2018). Fibroblast–Matrix Cross-Talk in Idiopathic Pulmonary Fibrosis: Cross-Links at the Crossroads. *Am. J. Respir. Cel Mol. Biol. 58* (5), 547–548. doi:10.1165/rcmb.2017-0402ED
- Blokland, K. E. C., Waters, D. W., Schuliga, M., Read, J., Pouwels, S. D., Grainge, C. L., et al. (2020). Senescence of IpF Lung Fibroblasts Disrupt Alveolar Epithelial Cell Proliferation and Promote Migration in Wound Healing. *Pharmaceutics 12* (4). doi:10.3390/pharmaceutics12040389
- Bochaton-Piallat, L., Gabbiani, G., and Hinz, B. (2016). The Myofibroblast in Wound Healing and Fibrosis: Answered and Unanswered Questions. *F1000Research 5* (0), 1–8. doi:10.12688/f1000research.8190.1
- Bolanos, A. L., Mendoza Milla, C., Lira, J. C., Ramírez, R., Checa, M., Barrera, L., et al. (2012). Role of Sonic Hedgehog in Idiopathic Pulmonary Fibrosis. *Am. J. Physiol. - Lung Cell Mol. Physiol. 303* (11), 978–990. doi:10.1152/ajplung.00184.2012
- Bonser, L., and Erle, D. (2017). Airway Mucus and Asthma: The Role of MUC5AC and MUC5B. *J. Clin. Med. 6* (12), 112. doi:10.3390/jcm6120112
- Burgess, J. K., and Irene, H. H. (2019). *Stem Cell-Based Therapy for Lung Disease*. Springer. doi:10.1007/978-3-030-29403-8
- Cahill, E. F., Kennelly, H., Carty, F., Mahon, B. P., and English, K. (2016). Hepatocyte Growth Factor Is Required for Mesenchymal Stromal Cell Protection against Bleomycin-Induced Pulmonary Fibrosis. *Stem Cell Transl Med 5* (10), 1307–1318. doi:10.5966/sctm.2015-0337
- Cao, H., Chen, X., Hou, J., Wang, C., Zou, X., Shen, Y., et al. (2019). The Shh/Gli Signaling cascade Regulates Myofibroblastic Activation of Lung-Resident Mesenchymal Stem Cells via the Modulation of Wnt10a Expression during Pulmonary Fibrogenesis. *Lab. Invest. 100* (3), 363–377. doi:10.1038/s41374-019-0316-8
- Cao, H., Wang, C., Chen, X., Hou, J., Zou, X., Shen, Y., et al. (2018). Inhibition of Wnt/ β -Catenin Signaling Suppresses Myofibroblast Differentiation of Lung Resident Mesenchymal Stem Cells and Pulmonary Fibrosis. *Scientific Rep. 8* (1), 1–14. doi:10.1038/s41598-018-28968-9
- Cao, S. S., and Kaufman, R. J. (2012). Unfolded Protein Response. *Curr. Biol. 22* (16), R622–R626. PMID: 22917505. doi:10.1016/j.cub.2012.07.004
- Cargnoni, A., Gibelli, L., Tosini, A., Signoroni, P. B., Nassuato, C., Arienti, D., et al. (2009). Transplantation of Allogeneic and Xenogeneic Placenta-Derived Cells Reduces Bleomycin-Induced Lung Fibrosis. *Cel Transplant. 18* (4), 405–422. doi:10.3727/096368909788809857
- Cerri, S., Monari, M., Guerrieri, A., Donatelli, P., Bassi, I., Garuti, M., et al. (2019). Real-life Comparison of Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: A 24-month Assessment. *Respir. Med. 159* (10), 105803. doi:10.1016/j.rmed.2019.105803
- Chanda, D., Otoupalova, E., Smith, S. R., Volckaert, T., Stijn, P. D., and Victor, J. T. (2019). Developmental Pathways in the Pathogenesis of Lung Fibrosis. *Mol. Aspects Med. 65* (7), 56–69. doi:10.1016/j.mam.2018.08.004
- Chen, S., Chen, X., Wu, X., Wei, S., Han, W., Lin, J., et al. (2017). Hepatocyte Growth Factor-Modified Mesenchymal Stem Cells Improve Ischemia/reperfusion-Induced Acute Lung Injury in Rats. *Gene Ther. 24* (1), 3–11. Epub 2016 Aug 24; PMID: 27556817. doi:10.1038/gt.2016.64
- Chen, X., Shi, C., Cao, H., Chen, L., Hou, J., Zou, X., et al. (2018). The Hedgehog and Wnt/ β -Catenin System Machinery Mediate Myofibroblast Differentiation of LR-MSCs in Pulmonary. *Cel Death Dis. 9* (6), 639. doi:10.1038/s41419-018-0692-9
- Chilosi, M., Poletti, V., Zamò, A., Lestani, M., Montagna, L., Piccoli, P., et al. (2003). Aberrant Wnt/ β -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis. *Am. J. Pathol. 162* (5), 1495–1502. PMID: 12707032; PMCID: PMC1851206. doi:10.1016/s0002-9440(10)64282-4
- Chong, S., Sato, S., Kolb, M., and Gaudie, J. (2019). Fibrocytes and Fibroblasts—Where Are We Now. *Int. J. Biochem. Cel Biol. 116* (August), 105595. doi:10.1016/j.biocel.2019.105595
- Cigna, N., Elika, F. M., Brayer, S., Marchal-Somme, J., Wémeau-Stervinou, L., Fabre, A., et al. (2012). The Hedgehog System Machinery Controls Transforming Growth Factor- β -dependent Myofibroblastic Differentiation in Humans: Involvement in Idiopathic Pulmonary Fibrosis. *Am. J. Pathol. 181* (6), 2126–2137. doi:10.1016/j.ajpath.2012.08.019
- Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., et al. (2016). Acute Exacerbation of Idiopathic Pulmonary Fibrosis an International Working Group Report. *Am. J. Respir. Crit. Care Med. 194* (3), 265–275. doi:10.1164/rccm.201604-0801CI
- Cruz, F. F., and Patricia, R. M. R. (2020). The Potential of Mesenchymal Stem Cell Therapy for Chronic Lung Disease. *Expert Rev. Respir. Med. 14* (1), 31–39. doi:10.1080/17476348.2020.1679628

- Dabrowska, S., Anna, A., and Janowski, M. (2021). Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cells and Extracellular Vesicles: Therapeutic Outlook for in Fl Ammatory and Degenerative Diseases. *Front. Immunol.* 11 (2), 591065. doi:10.3389/fimmu.2020.591065
- David, M. H., and Cory, M. H. (2017). Heterogeneity of Fibroblasts and Myofibroblasts in Pulmonary Fibrosis. *Physiol. Behav.* 176 (3), 139–148. doi:10.1007/s40139-017-0134-x
- Dinh, P., Uyen, C. D., Paudel, D., Brochu, H., Kristen, D. P., Gracieux, M. C., et al. (2020). Inhalation of Lung Spheroid Cell Secretome and Exosomes Promotes Lung Repair in Pulmonary Fibrosis. *Nat. Commun.* 11 (1). doi:10.1038/s41467-020-14344-7
- Dominici, M., Le Blanc, K., Mueller, L., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., et al. (2006). Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement. *Cytotherapy* 8 (4), 315–317. doi:10.1080/14653240600855905
- Doubková, M., Radová, L., Michaela, P., Trizuljak, J., Karol, P., Svobodová, K., et al. (2019). A Novel Germline Mutation of the *SFTPA1* Gene in Familial Interstitial Pneumonia, 4–9. doi:10.1038/s41439-019-0044-z
- Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., et al. (2018). Analysis of Protein-Altering Variants in Telomerase Genes and Their Association with MUC5B Common Variant Status in Patients with Idiopathic Pulmonary Fibrosis: a Candidate Gene Sequencing Study. *Lancet Respir. Med.* 6 (8), 603–614. doi:10.1016/S2213-2600(18)30135-8
- El Agha, E., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., and Kwapiszewska, G. (2017). Two-Way Conversion Between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. *Cell Stem Cell* 20 (4), 571. doi:10.1016/j.stem.2017.03.011. Erratum for: *Cell Stem Cell*. 2017 Feb 20;20(2):261–273.e3. PMID: 28388434
- Enes, R. S., Ahrman, E., Palani, A., Hallgren, O., Bjermer, L., Malmström, A., et al. (2017). Quantitative Proteomic Characterization of Lung-MSc and Bone Marrow-MSc Using DIA-Mass Spectrometry. Springer, 1–12. doi:10.1038/s41598-017-09127-y
- Ferguson, S. W., and Nguyen, J. (2016). Exosomes as Therapeutics: The Implications of Molecular Composition and Exosomal Heterogeneity. *J. Controlled Release* 228, 179–190. doi:10.1016/j.jconrel.2016.02.037
- Fernandez, I. E., and Oliver, E. (2012). New Cellular and Molecular Mechanisms of Lung Injury and Fibrosis in Idiopathic Pulmonary Fibrosis. *The Lancet* 380 (9842), 680–688. doi:10.1016/S0140-6736(12)61144-1
- Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., et al. (2013). Genome-wide Association Study Identifies Multiple Susceptibility Loci for Pulmonary Fibrosis. *Nat. Genet.* 45 (6), 613–620. doi:10.1038/ng.2609
- Fomby, P., Cherlin, A. J., Hadjizadeh, A., Doillon, C. J., Sueblinvong, V., Weiss, D. J., et al. (2010). Stem Cells and Cell Therapies in Lung Biology and Diseases: Conference Report. *Ann. Am. Thorac. Soc.* 12 (3), 181–204. doi:10.1002/term
- Fujita, Y., Kadota, T., Araya, J., Ochiya, T., and Kuwano, K. (2018). Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases. *J. Clin. Med.* 7 (10), 355. doi:10.3390/jcm7100355
- Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H. L., et al. (2016). Mesenchymal Stem Cells and Immunomodulation: Current Status and Future Prospects. *Cel Death Dis.* 7 (1). doi:10.1038/cddis.2015.327
- Gazdic, M., Volarevic, V., Arsenijevic, N., and Stojkovic, M. (2015). Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases. *Stem Cell Rev. Rep.* 11 (2), 280–287. doi:10.1007/s12015-014-9583-3
- Geissler, S., Textor, M., Schmidt-Bleek, K., Klein, O., Thiele, M., Ellinghaus, A., et al. (2013). In Serum Veritas-In Serum Sanitas? Cell Non-autonomous Aging Compromises Differentiation and Survival of Mesenchymal Stromal Cells via the Oxidative Stress Pathway. *Cell Death Dis* 4 (12), e970, 2013. PMID: 24357801; PMCID: PMC3877568. doi:10.1038/cddis.2013.501
- Gharibi, B., and Hughes, F. J. (2012). Effects of Medium Supplements on Proliferation, Differentiation Potential, and *In Vitro* Expansion of Mesenchymal Stem Cells. *Stem Cell Transl Med* 1 (11), 771–782. Epub 2012 Oct 23. PMID: 23197689; PMCID: PMC3659663. doi:10.5966/sctm.2010-0031
- Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., David, K., Teherani, A., et al. (2014). A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* 2014, 2083–2092. doi:10.1056/NEJMoa1402582
- Glassberg, M. K., Julia, M., Rebecca, L. T., Emmanuelle, S. S., Gustavo, A. R., Darcy, D., et al. (2017). Allogeneic Human Mesenchymal Stem Cells in Patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. *Chest* 151 (5), 971–981. doi:10.1016/j.chest.2016.10.061
- Gokey, J. J., Sridharan, A., Xu, Y., Green, J., Carraro, G., Stripp, B. R., et al. (2018). Active Epithelial Hippo Signaling in Idiopathic Pulmonary Fibrosis. *JCI insight* 3 (6), e98738. doi:10.1172/jci.insight.98738
- Golchin, A., Seyedjafari, E., and Ardeshtyrajimi, E. (2020). Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. *Stem Cell Rev. Rep.* 16 (3), 427–433. doi:10.1007/s12015-020-09973-w
- Green, J., Endale, M., Auer, H., and Anne Karina, T. P. (2016). Diversity of Interstitial Lung Fibroblasts Is Regulated by Platelet-Derived Growth Factor Receptor a Kinase Activity. *Am. J. Respir. Cel Mol. Biol.* 54 (4), 532–545. doi:10.1165/rcmb.2015-0095OC
- Gu, Z., Cao, X., Jiang, J., Li, L., Da, Z., Liu, H., et al. (2012). Upregulation of p16INK4A Promotes Cellular Senescence of Bone Marrow-Derived Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients. *Cell Signal* 24 (12), 2307–2314. Epub 2012 Jul 20. PMID: 22820504. doi:10.1016/j.cellsig.2012.07.012
- Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., et al. (2018). The European IPF Registry (eurIPFreg): Baseline Characteristics and Survival of Patients With Idiopathic Pulmonary Fibrosis. *Respir Res.* 28 (1), 141. doi:10.1186/s12931-018-0845-5
- Guescini, M., Genedani, S., Stocchi, V., and Agnati, L. F. (2010). Astrocytes and Glioblastoma Cells Release Exosomes Carrying mtDNA. *J. Neural Transm.* 117 (1), 1–4. doi:10.1007/s00702-009-0288-8
- Hancock, L. A., Hennessy, C. E., Solomon, G. M., Dobrinskikh, E., Estrella, A., Hara, N., et al. (2018). Muc5b Overexpression Causes Mucociliary Dysfunction and Enhances Lung Fibrosis in Mice. *Nat. Commun.* 9 (1), 1–10. doi:10.1038/s41467-018-07768-9
- Harrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., and Volarevic, V. (2019). Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome. *Cells* 8 (5), 467. doi:10.3390/cells8050467
- Hasaneen, N. A., Cao, J., Pulkoski-gross, A., Zucker, S., and Hussein, D. F. (2016). Extracellular Matrix Metalloproteinase Inducer (EMMPRN) Promotes Lung Fibroblast Proliferation, Survival and Differentiation to Myofibroblasts. *Respir. Res.* 17, 1–14. doi:10.1186/s12931-016-0334-7
- Henderson, W., Chi, E. Y., Ye, X., Nguyen, C., Tien, Y. T., Zhou, B., et al. (2010). Inhibition of Wnt/ β -catenin/CREB Binding Protein (CBP) Signaling Reverses Pulmonary Fibrosis. *14309–14314*. doi:10.1073/pnas.1001520107
- Herrera, I., Cisneros, J., Maldonado, M., Ramirez, R., Ortiz-Quintero, B., Elena, A., et al. (2013). Matrix Metalloproteinase (MMP)-1 Induces Lung Alveolar Epithelial Cell Migration and Proliferation, Protects from Apoptosis, and Represses Mitochondrial Oxygen Consumption. *J. Biol. Chem.* 288 (36), 25964–25975. doi:10.1074/jbc.M113.459784
- Hinz, B. (2012). Mechanical Aspects of Lung Fibrosis: A Spotlight on the Myofibroblast. *Proc. Am. Thorac. Soc.* 9 (3), 137–147. doi:10.1513/pats.201202-017AW
- Hinz, B., Phan, S. H., Thannickal, V. J., and Galli, A. (2007). Marie Luce Bochaton-Piallat, Giulio Gabbiani. 2007. The Myofibroblast: One Function, Multiple Origins. *Am. J. Pathol.* 170 (6), 1807–1816. doi:10.2353/ajpath.2007.070112
- Hoffman, A. M., Paxson, J. A., Mazan, M. R., Davis, A. M., Tyagi, S., Murthy, S., et al. (2011). Lung-derived Mesenchymal Stromal Cell post-transplantation Survival, Persistence, Paracrine Expression, and Repair of Elastase-Injured Lung. *Stem Cell Dev* 20 (10), 1779–1792. Epub 2011 Jul 6. PMID: 21585237; PMCID: PMC3182034. doi:10.1089/scd.2011.0105
- Horowitz, J. C., and Thannickal, V. J. (2019). Mechanisms for the Resolution of Organ Fibrosis. *Physiology* 34 (1), 43–55. doi:10.1152/physiol.00033.2018
- Hu, H. H., Chen, D. Q., Wang, Y. N., Feng, Y. L., Cao, G., Vaziri, N. D., et al. (2018). New Insights into TGF- β /Smad Signaling in Tissue Fibrosis. *Chem. Biol. Interact* 292, 76–83. Epub 2018 Jul 11. PMID: 30017632. doi:10.1016/j.cb.2018.07.008
- Huang, K., Kang, X., Wang, X., Wu, S., Xiao, J., Li, Z., et al. (2015). Conversion of Bone Marrow Mesenchymal Stem Cells into Type II Alveolar Epithelial Cells Reduces Pulmonary Fibrosis by Decreasing Oxidative Stress in Rats. *Mol. Med. Rep.* 11, 1685–1692. doi:10.3892/mmr.2014.2981
- Huleihel, L., Sellares, J., Cardenes, N., Álvarez, D., Faner, R., Sakamoto, K., et al. (2017). Modified Mesenchymal Stem Cells Using miRNA Transduction Alter Lung Injury in a Bleomycin Model. *Am. J. Physiol. - Lung Cel. Mol. Physiol.* 313, L92–L103. doi:10.1152/ajplung.00323.2016

- Hung, C., Linn, G., Chow, Y., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A., et al. (2013). Role of Lung Pericytes and Resident Fibroblasts in the Pathogenesis of Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 188 (7), 820–830. PMID: 23924232; PMCID: PMC3826269. doi:10.1164/rccm.201212-2297OC
- Iwayama, T., Steele, C., Yao, L., Dozmorov, M. G., Karamichos, D., Wren, J. D., et al. (2015). PDGFR α Signaling Drives Adipose Tissue Fibrosis by Targeting Progenitor Cell Plasticity. *Genes Dev.* 29 (11), 1106–1119. doi:10.1101/gad.260554.115
- Jaffar, J., Griffiths, K., Oveissi, S., Duan, M., Foley, M., Glaspole, I., et al. (2020). CXCR4+ cells Are Increased in Lung Tissue of Patients with Idiopathic Pulmonary Fibrosis. *Respir. Res.* 21 (1), 1–16. doi:10.1186/s12931-020-01467-0
- Jarvinen, L., Badri, L., Scott, W., Standiford, T. J., Toews, G. B., David, J., et al. (2021). Lung Resident Mesenchymal Stem Cells Isolated from Human Lung Allografts Inhibit T Cell Proliferation via a Soluble Mediator. *J. Immunol.* 181 (6), 4389–4396. doi:10.4049/jimmunol.181.6.4389
- Jenkins, R. G., Moore, B. B., Chambers, R. C., Oliver, E., Konigshoff, M., Kolb, M., et al. (2017). An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. *Am. J. Respir. Cell Mol. Biol.* 56 (5), 667–679. doi:10.1165/rcmb.2017-0096ST
- Jessica Germaine, S., Teresa Pay, M., Lara Compte, C., Olid, M., Bermudo, G., Portillo, K., et al. (2020). Mapping IPF Helps Identify Geographic Regions at Higher Risk for Disease Development and Potential Triggers. *Respirology* 26, 1–8. doi:10.1111/resp.13973
- Jiang, Y., Mishima, H., Sakai, S., Liu, Y. K., Ohyabu, Y., and Uemura, T. (2008). Gene Expression Analysis of Major Lineage-Defining Factors in Human Bone Marrow Cells: Effect of Aging, Gender, and Age-Related Disorders. *J. Orthop. Res.* 26 (7), 910–917. PMID: 18302252. doi:10.1002/jor.20623
- Jun, D., Garat, C., West, J., Thorn, N., Chow, K., Cleaver, T., et al. (2011). The Pathology of Bleomycin-Induced Fibrosis Is Associated with Loss of Resident Lung Mesenchymal Stem Cells that Regulate Effector T-Cell Proliferation. *Stem Cells* 29 (4), 725–735. doi:10.1002/stem.604
- Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., et al. (2017). Baseline Characteristics of Idiopathic Pulmonary Fibrosis: Analysis From the Australian Idiopathic Pulmonary Fibrosis Registry. *Eur. Respir. J.* 49 (2), 1601592. doi:10.1183/13993003.01592-2016. Erratum in: *Eur. Respir. J.* 2017 Mar 29;49(3): PMID: 28232409
- Karki, S., Suroliya, R., David Hock, T., Guroji, P., Zolak, J. S., Ryan, D., et al. (2014). Wilms' Tumor 1 (Wt1) Regulates Pleural Mesothelial Cell Plasticity and Transition into Myofibroblasts in Idiopathic Pulmonary Fibrosis. *FASEB J.* 28 (3), 1122–1131. doi:10.1096/fj.13-236828
- Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., et al. (2019). Metformin Induces Lipogenic Differentiation in Myofibroblasts to Reverse Lung Fibrosis. *Nat. Commun.* 10 (1), 2987, 2019. PMID: 31278260; PMCID: PMC6611870. doi:10.1038/s41467-019-10839-0
- Kim, K. K., Kugler, M. C., Paul, J., Robillard, L., Galvez, M. G., Alexis, M., et al. (2006). Alveolar Epithelial Cell Mesenchymal Transition Develops *In Vivo* during Pulmonary Fibrosis and Is Regulated by the Extracellular Matrix. *Proc. Natl. Acad. Sci. United States America* 103 (35), 13180–13185. doi:10.1073/pnas.0605669103
- Kim, S. Y., Lee, J. H., Kim, H. J., Park, M. K., Huh, J. W., Ro, J. Y., et al. (2012). Mesenchymal Stem Cell-Conditioned media Recovers Lung Fibroblasts from Cigarette Smoke-Induced Damage. *Am. J. Physiol. - Lung Cell Mol. Physiol.* 302 (9), L891–L908. doi:10.1152/ajplung.00288.2011
- King, T. E., Pardo, A., and Selman, M. (2011). Idiopathic Pulmonary Fibrosis. *The Lancet* 378 (9807), 1949–1961. doi:10.1016/S0140-6736(11)60052-4
- Kirkland, J. L., and Tchkonja, T. (2017). Cellular Senescence: A Translational Perspective. *EBioMedicine* 21, 21–28. doi:10.1016/j.ebiom.2017.04.013
- Kis, K., Liu, X., James, S., and Hagood, S. (2011). Myofibroblast Differentiation and Survival in Fibrotic Disease. *Expert Rev. Mol. Med.* 13 (2), e27. doi:10.1017/S1462399411001967
- Kleaveland, K. R., Miranda, V., Yang, J., Agarwal, M., Rippe, R. A., Bethany, B., et al. (2014). Fibrocytes Are Not an Essential Source of Type I Collagen during Lung Fibrosis. *J. Immunol.* 193 (10), 5229–5239. doi:10.4049/jimmunol.1400753
- Klein, D. (2020). Lung Multipotent Stem Cells of Mesenchymal Nature: Cellular Basis. *Clin. relevance implications Stem Cel. Ther.* 5, 1–38. doi:10.1089/ars.2020.8190
- Kotani, T., Masutani, R., Suzuka, T., Oda, K., Makino, S., and Li, M. (2017). Anti-Inflammatory and Anti-Fibrotic Effects of Intravenous Adipose-Derived Stem Cell Transplantation in a Mouse Model of Bleomycin-Induced Interstitial Pneumonia. *Sci. Rep.* 7 (1), 14608, 2017. Erratum in: *Sci Rep.* 2018 Jan 8;8(1):454. Erratum in: *Sci Rep.* 2018 Mar 6;8(1):4222. PMID: 29097816.
- Kramann, R., Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., et al. (2015). Perivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis. *Cell Stem Cell* 16 (1), 51–66. doi:10.1016/j.stem.2014.11.004
- Kropfski, J. A., Daphne, B. M., Cheryl, M., Vasilij, V. P., Choi, L., Joyce, E. J., et al. (2014). A Novel Dyskerin (DKC1) Mutation Is Associated with Familial Interstitial Pneumonia. *CHEST* 146 (1), e1–7. doi:10.1378/chest.13-2224
- Kropfski, J. A., Jason, M. P., Donald, F. Z., Peter, F. C., Markin, C., Garnett, E. T., et al. (2015). Extensive Phenotyping of Individuals at Risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease. *Am. J. Respir. Crit. Care Med.* 191 (4), 417–426. doi:10.1164/rccm.201406-1162OC
- Kruk, D. M. L. W., Wisman, M., de Bruin, H. G., Lodewijk, M. E., Danique, J., Borghuis, T., et al. (2021). Abnormalities in Reparative Function of Lung-Derived Mesenchymal Stromal Cells in Emphysema. *Am. J. Physiology-Lung Cell Mol. Physiol.* marzo 320. doi:10.1152/ajplung.00147.2020
- Lan, Y. W., Choo, K. B., Chen, C. M., Hung, T. H., Chen, Y. Bin., Hsieh, C. H., et al. (2015). Hypoxia-preconditioned Mesenchymal Stem Cells Attenuate Bleomycin-Induced Pulmonary Fibrosis. *Stem Cel Res. Ther.* 6, 1–17. doi:10.1186/s13287-015-0081-6
- Larsson, H., Le Blanc, K., Eriksson, L., Bjermer, L., and Scheding, S. (2016). *MSC from Fetal and Adult Lungs Possess Lung-specific Properties Compared to Bone Marrow-Derived*. Nature Publishing Group, 1–10. doi:10.1038/srep29160
- Lederer, D. J., and Martinez, F. J. (2018). Idiopathic Pulmonary Fibrosis. *New Engl. J. Med.* 378 (19), 1811–1823. doi:10.1056/NEJMra1705751
- Lee, J. K., Park, S., Jung, B., Jeon, Y., Lee, Y., Kim, K., et al. (2013). Exosomes Derived from Mesenchymal Stem Cells Suppress Angiogenesis by Down-Regulating VEGF Expression in Breast Cancer. *Cells* 8 (12). doi:10.1371/journal.pone.0084256
- Lee, S., Lee, E., Lee, S., Kim, J., Shim, J., Shin, C., et al. (2014). The Effect of Adipose Stem Cell Therapy on Pulmonary Fibrosis Induced by Repetitive Intratracheal Bleomycin in Mice. *Exp. Lung Res.* 40 (3), 117–125. doi:10.3109/01902148.2014.881930
- Lehmann, M., Hu, Q., Hu, Y., Hafner, K., Costa, R., van den Berg, A., et al. (2020). Chronic Wnt/ β -Catenin Signaling Induces Cellular Senescence in Lung Epithelial Cells. *Cell Signal.* 70 (October), 109588. doi:10.1016/j.cellsig.2020.109588
- Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-wasek, W., Alsafadi, H. N., et al. (2017). Senolytic Drugs Target Alveolar Epithelial Cell Function and Attenuate Experimental. *Eur. Respir. J.* 50 (2), 1602367. doi:10.1183/13993003.02367-2016
- Ley, B., Collard, H. R., and King, T. E. (2011). Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 183 (4), 431–440. doi:10.1164/rccm.201006-0894CI
- Ley, B., Newton, C. A., Arnould, I., Elicker, B. M., Henry, T. S., Vittinghoff, E., et al. (2017). The MUC5B Promoter Polymorphism and Telomere Length in Patients with Chronic Hypersensitivity Pneumonitis: an Observational Cohort-Control Study. *Lancet Respir. Med.* 5 (8), 639–647. doi:10.1016/S2213-2600(17)30216-3
- Li, F., Han, F., Li, H., Zhang, J., Qiao, X., Shi, J., et al. (2017a). Human Placental Mesenchymal Stem Cells of Fetal Origins-Alleviated Inflammation and Fibrosis by Attenuating MyD88 Signaling in Bleomycin-Induced Pulmonary Fibrosis Mice. *Mol. Immunol.* 90, 11–21. doi:10.1016/j.molimm.2017.06.032
- Li, Y., Wu, Q., Wang, Y., Li, L., Bu, H., and Bao, J. (2017b). Senescence of Mesenchymal Stem Cells (Review). *Int. J. Mol. Med.* 39 (4), 775–782. Epub 2017 Mar 9. PMID: 28290609. doi:10.3892/ijmm.2017.2912

- Liu, J., Ding, Y., Liu, Z., and Liang, X. (2020). Senescence in Mesenchymal Stem Cells: Functional Alterations, Molecular Mechanisms, and Rejuvenation Strategies. *Front Cel Dev Biol* 8, 258, 2020. PMID: 3. doi:10.3389/fcell.2020.00258
- López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of Aging. *Cell* 153 (6), 1194–1217. PMID: 23746838; PMCID: PMC3836174. doi:10.1016/j.cell.2013.05.039
- Lou, G., Chen, Z., Zheng, M., and Liu, E. Y. (2017). Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Liver Diseases. *Exp. Mol. Med.* 49 (6), e346. doi:10.1038/emm.2017.63
- Maguire, Greg. (2013). Stem Cell Therapy without Cells. *Communicative Integr. Biol.* 6 (6), e2663. doi:10.4161/cib.26631
- Mansouri, N., Willis, G. R., Fernandez-Gonzalez, A., Reis, M., Nassiri, S., Alex Mitsialis, S., et al. (2019). Mesenchymal Stromal Cell Exosomes Prevent and Revert Experimental Pulmonary Fibrosis through Modulation of Monocyte Phenotypes. *JCI Insight* 4 (21), 1–17. doi:10.1172/jci.insight.128060
- Marchioni, A., Tonelli, R., Rossi, G., Spagnolo, P., Luppi, F., Cerri, S., et al. (2020). Ventilatory Support and Mechanical Properties of the Fibrotic Lung Acting as a "squishy ball". *Ann. Intensive Care* 10 (1), 13, 2020. PMID: 32020548; PMCID: PMC7000609. doi:10.1186/s13613-020-0632-6
- Marriott, S., Baskir, R. S., Gaskill, C., Menon, S., Carrier, E. J., Williams, J., et al. (2014). ABCG2pos Lung Mesenchymal Stem Cells Are a Novel Pericyte Subpopulation that Contributes to Fibrotic Remodeling. *Am. J. Physiol. - Cell Physiol.* 307 (8), C684–C698. doi:10.1152/ajpcell.00114.2014
- Martin, A., Jahn, A., Rio, C., Iglesias, A., Mercader, J., Montes, A., et al. (2020). Characterizing Lung Resident Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis. *Eur. Respir. J.* 56 (Suppl. 64). doi:10.1183/13993003.congress-2020.457
- Martin-Medina, A., Lehmann, M., Olivier, B., Hermann, S., Baarsma, H. A., Wagner, D. E., et al. (2018). Increased Extracellular Vesicles Mediate Wnt5A Signaling in Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 198 (12), 1527–1538. doi:10.1164/rccm.201708-1580OC
- Massagué, J. (2014). TGFβ Signaling in Context. *Nat. Rev. Mol. Cell Biol* 13 (10), 616–630. doi:10.1038/nrm3434.TGF
- Masterson, C. H., Curley, G. F., and Laffey, J. G. (2019). Modulating the Distribution and Fate of Exogenously Delivered. *MSCs enhance Ther. potential: knowns unknowns* 7 (Suppl. 1), 1–21. doi:10.1186/s40635-019-0235-4
- Mastrolia, I., Foppiani, E. M., Alba, M., Candini, O., Samarelli, A. V., Grisendi, G., et al. (2019). Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. *Stem Cell Translational Med.* 8 (11), 1135–1148. doi:10.1002/sctm.19-0044
- Meng, F., Xu, R., Wang, S., Xu, Z., Zhang, C., Li, Y., et al. (2020). Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients with COVID-19: a Phase 1 Clinical Trial. *Signal. Transduction Targeted Ther.* 5 (1). doi:10.1038/s41392-020-00286-5
- Meng, X. M., Nikolic-Paterson, D. J., and Lan, H. Y. (2016). TGF-β: The Master Regulator of Fibrosis. *Nat. Rev. Nephrol.* 12 (6), 325–338. doi:10.1038/nrneph.2016.48
- Michalski, J. E., and Schwartz, D. A. (2020). Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis. *J. Inflamm. Res.* 13, 1305–1318. doi:10.2147/JIR.S280958
- Moeller, A., Kjetil, A., Warburton, D., Gaudie, J., and Kolb, M. (2008). The Bleomycin Animal Model: A Useful Tool to Investigate Treatment Options for Idiopathic Pulmonary Fibrosis? *Int. J. Biochem. Cell Biol.* 40 (3), 362–382. doi:10.1016/j.biocel.2007.08.011
- Moll, G., James, A. A., Julian, K.-M., Karen, B., Olle, R., Hans, D. V., et al. (2019). Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. *Trends Mol. Med.* 25 (2), 149–163. doi:10.1016/j.molmed.2018.12.006
- Moodley, Y., Atienza, D., Manuelpillai, U., Samuel, C. S., Tchongue, J., Ilancheran, S., et al. (2009). Human Umbilical Cord Mesenchymal Stem Cells Reduce Fibrosis of Bleomycin-Induced Lung Injury. *Am. J. Pathol.* 175 (1), 303–313. doi:10.2353/ajpath.2009.080629
- Moodley, Y., Vaghjiani, V., Chan, J., Baltic, S., Ryan, M., Tchongue, J., et al. (2013). Anti-Inflammatory Effects of Adult Stem Cells in Sustained Lung Injury: A Comparative Study. *PLoS One* 8, e69299. doi:10.1371/journal.pone.0069299
- Moore, B. B., Jill, E. K., Victor, J. T., Cooke, K., Moore, T. A., Hogaboam, C., et al. (2005). CCR2-mediated Recruitment of Fibrocytes to the Alveolar Space after Fibrotic Injury. *Am. J. Pathol.* 166 (3), 675–684. doi:10.1016/S0002-9440(10)62289-4
- Mora, A. L., Rojas, M., Pardo, A., and Selman, M. (2017). Emerging Therapies for Idiopathic Pulmonary Fibrosis, a Progressive Age-Related Disease. *Nat. Rev. Drug Discov.* 16 (11), 755–772. doi:10.1038/nrd.2017.170
- Ni, K., Liu, M., Zheng, J., Wen, L., Chen, Q., Zheng, X., et al. (2018). PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice. *Am. J. Respir. Cell Mol. Biol.* 58 (6), 684–695. doi:10.1165/rcmb.2017-0326OC
- Noble, P. W., Albera, C., Williamson, Z. B., Ulrich, C., Glassberg, M. K., Kardatzke, D., et al. (2011). Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (CAPACITY): Two Randomised Trials. *The Lancet* 377 (9779), 1760–1769. doi:10.1016/S0140-6736(11)60405-4
- Noguchi, S., Saito, A., and Nagase, T. (2018). YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer. *Int. J. Mol. Sci.* 19 (11). doi:10.3390/ijms19113674
- Nureki, S. I., Tomer, Y., Venosa, A., Katzen, J., Russo, A. J., Jamil, S., et al. (2018). Expression of Mutant Sftpc in Murine Alveolar Epithelia Drives Spontaneous Lung Fibrosis. *J. Clin. Invest.* 128 (9), 4008–4024. doi:10.1172/JCI99287
- Ono, M., Ohkouchi, S., Kanehira, M., Tode, N., Kobayashi, M., Ebina, M., et al. (2015). Mesenchymal Stem Cells Correct Inappropriate Epithelial-Mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1. *Mol. Ther.* 23, 549–560. doi:10.1038/mt.2014.217
- Ortiz, L. A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, N., et al. (2003). Mesenchymal Stem Cell Engraftment in Lung Is Enhanced in Response to Bleomycin Exposure and Ameliorates its Fibrotic Effects. *Proc. Natl. Acad. Sci. United States America* 100 (14), 8407–8411. doi:10.1073/pnas.1432929100
- Ortiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., et al. (2007). Interleukin 1 Receptor Antagonist Mediates the Antiinflammatory and Antifibrotic Effect of Mesenchymal Stem Cells during Lung Injury. *Proc. Natl. Acad. Sci. U. S. A.* 104, 11002–11007. doi:10.1073/pnas.0704421104
- Pardo, A., Gibson, K., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., et al. (2005). Up-regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis. *PLoS Med.* 2 (9), 0891–0903. doi:10.1371/journal.pmed.0020251
- Pardo, A., and Moisés Selman, E. (2021). The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Cell Mol. Biol.* 64 (2), 163–172. doi:10.1165/rcmb.2020-0373ps
- Phan, Sem. H. (2002). The Myofibroblast in Pulmonary Fibrosis. *Chest* 122 (6 Suppl. L), 286S–289S. doi:10.1378/chest.122.6_suppl.286S
- Phan, T., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Hussein Eid, A., Giuseppe Fois, A., et al. (2020). Emerging Cellular and Molecular Determinants of Idiopathic Pulmonary Fibrosis. *Cell Mol. Life Sci.* 78, 2031–2057. doi:10.1007/s00018-020-03693-7
- Phillips, R. J., Burdick, M. D., Hong, K., Lutz, M. A., Murray, L. A., Ying Xue, Y., et al. (2004). Circulating Fibrocytes Traffic to the Lungs in Response to CXCL12 and Mediate Fibrosis. *J. Clin. Invest.* 114 (3), 438–446. doi:10.1172/JCI200420997
- Plantier, L., Crestani, B., Wert, S. E., Dehoux, M., Zweytick, B., Guenther, A., et al. (2011). Ectopic Respiratory Epithelial Cell Differentiation in Bronchiolised Distal Airspaces in Idiopathic Pulmonary Fibrosis. *Thorax* 66 (8), 651–657. Epub 2011 Mar 21; PMID: 21422041. doi:10.1136/thx.2010.151555
- Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and Balch, W. E. (2009). Biological and Chemical Approaches to Diseases of Proteostasis Deficiency. *Annu. Rev. Biochem.* 78, 959–991. PMID: 19298183. doi:10.1146/annurev.biochem.052308.114844
- Qiu, T., Tian, Y., Gao, Y., Ma, M., Li, H., Liu, X., et al. (2019). PTEN Loss Regulates Alveolar Epithelial Cell Senescence in Pulmonary Fibrosis Depending. *Akt activation* 11 (18), 7492–7509. doi:10.18632/aging.102262 on
- Raghu, G., Harold, C., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., et al. (2011). An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. *Am. J. Respir. Crit. Care Med.* 183 (6), 788–824. doi:10.1164/rccm.2009-040GL.Ricciardi

- Ricciardi, M., Giorgio, M., Francesco, B., Giulio, B., Luciano, P., and Nwabo, K. A. H. (2012). Comparison of Epithelial Differentiation and Immune Regulatory Properties of Mesenchymal Stromal Cells Derived from Human Lung and Bone Marrow. *PLoS One* 7 (5), 1–10. doi:10.1371/journal.pone.0035639
- Richeldi, L., Collard, H. R., and Jones, M. G. (2017). Idiopathic Pulmonary Fibrosis. *The Lancet* 389 (10082), 1941–1952. doi:10.1016/S0140-6736(17)30866-8
- Rock, J. R., Christina, E., Michael, J., Xue, Y., Harris, J. R., Liang, J., et al. (2011). “Multiple Stromal Populations Contribute to Pulmonary Fibrosis without Evidence for Epithelial to Mesenchymal Transition,” in *Proceedings of the National Academy of Sciences of the United States of America* (US: NIH). doi:10.1073/pnas.1117988108
- Rolandsson, S., Andersson Sjöland, S., Brune, J. C., Li, H., Kassem, M., Mertens, F., et al. (2014). Primary Mesenchymal Stem Cells in Human Transplanted Lungs Are CD90/CD105 Perivascularly Located Tissue-Resident Cells. *BMJ Open Respir. Res.* 1 (1), 1–12. doi:10.1136/bmjresp-2014-000027
- Roy, M. G., Livraghi-butrico, S., Fletcher, A. A., Mcelwee, M. M., Scott, E. E., Ryan, M. B., et al. (2013). Muc5b Is Required for Airway Defence. *Nature* 505 (7483), 412–416. doi:10.1038/nature12807
- Rubio, G. A., Elliot, S. J., Wikramanayake, T., Xia, X., Pereira-simon, S., Seth, R., et al. (2017). Mesenchymal Stromal Cells Prevent Bleomycin-Induced Lung and Skin Fibrosis in Aged Mice and Restore Wound Healing †. *J. Cell Physiol* 233 (8), 5503–5512. doi:10.1002/jcp.26418
- Ryu, J. H., Teng, M., Daniels, C. E., Hartman, T. E., Yi, E. S., Utz, J. P., et al. (2014). Idiopathic Pulmonary Fibrosis: Evolving Concepts. *Mayo Clinic Proc.* 89 (8), 1130–1142. doi:10.1016/j.mayocp.2014.03.016
- Schröder, M., and Kaufman, R. J. (2005). The Mammalian Unfolded Protein Response. *Annu. Rev. Biochem.* 74, 739–789. PMID: 15952902. doi:10.1146/annurev.biochem.73.011303.074134
- Scotton, C. J., and Chambers, R. C. (2007). Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus. *Chest* 132 (4), 1311–1321. doi:10.1378/chest.06-2568
- Seibold, M. A., Smith, R. W., Urbaneck, C., Steve, D. G., Cosgrove, G. P., Brown, K. K., et al. (2013). The Idiopathic Pulmonary Fibrosis Honeycomb Cyst Contains A Mucociliary Pseudostratified Epithelium. *PLoS ONE* 8 (3). doi:10.1371/journal.pone.0058658
- Selman, M., and Pardo, A. (2020). The Leading Role of Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis. *Cell Signal.* 66 (November 2019), 109482. doi:10.1016/j.cellsig.2019.109482
- Sgalla, G., Coconcelli, E., Tonelli, R., and Richeldi, L. (2016). Novel Drug Targets for Idiopathic Pulmonary Fibrosis. *Expert Rev. Respir. Med.* 10 (4), 393–405. doi:10.1586/17476348.2016.1152186
- Shah, T. G., Predescu, D., and Predescu, S. (2019). Mesenchymal Stem Cells-derived Extracellular Vesicles in Acute Respiratory Distress Syndrome: a Review of Current Literature and Potential Future Treatment Options. *Clin. Translational Med.* 8 (1), 4–9. doi:10.1186/s40169-019-0242-9
- Shentu, T. P., Huang, T. S., Cernelc-Kohan, M., Chan, J., Wong, S. S., Espinoza, C. R., et al. (2017). Thy-1 Dependent Uptake of Mesenchymal Stem Cell-Derived Extracellular Vesicles Blocks Myofibroblastic Differentiation. *Scientific Rep.* 7 (1), 1–11. doi:10.1038/s41598-017-18288-9
- Shi, J., Li, F., Luo, M., Wei, J., and Liu, X. (2017). Distinct Roles of Wnt/ β -Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. *Mediators Inflamm.* 2017, 3520581. doi:10.1155/2017/3520581
- Sinclair, K. A., Yerkovich, S. T., Chen, T., McQualter, J. L., Hopkins, P. M. A., Wells, C. A., et al. (2016). Mesenchymal Stromal Cells Are Readily Recoverable from Lung Tissue, but Not the Alveolar Space, in Healthy Humans. *Stem Cells* 34 (10), 2548–2558. doi:10.1002/stem.2419
- Stanley, S. E., Gable, D. L., Wagner, C. L., Carlile, T. M., Vidya Sagar, H., Joshua, D. P., et al. (2016). Loss-of-function Mutations in the RNA Biogenesis Factor NAF1 Predispose to Pulmonary Fibrosis – Emphysema. *Sci. Transl Med.* 8 (351), 1–10. doi:10.1126/scitranslmed.aaf7837
- Steele, M. P., Brown, K. K., James, E. L., Tasha E Fingerlin, D., Zhang, W., Adler, K. B., et al. (2011). A Common. *N. Engl. J. Med.* 364 (16), 1503–1512.
- Steens, J., Klar, L., Hansel, C., Alexis, S., Hager, T., Jendrossek, V., et al. (2021). The Vascular Nature of Lung-Resident Mesenchymal Stem Cells. *Stem Cell Translational Med.* 10 (1), 128–143. doi:10.1002/sctm.20-0191
- Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., et al. (2015). Exome Sequencing Links Mutations in PARN and RTEL1 with Familial Pulmonary Fibrosis and Telomere Shortening. *Nat. Genet.* 47 (5), 512–517. doi:10.1038/ng.3278
- Summers, M. E., Richmond, B. W., Kropski, J. A., Majka, S. A., Bastarache, J. A., Hatzopoulos, A. K., et al. (2021). Balanced Wnt/Dickkopf-1 Signaling by Mesenchymal Vascular Progenitor Cells in the Microvascular Niche Maintains Distal Lung Structure and Function. *Am. J. Physiol. Cell Physiol* 320 (1), C119–C131. Epub 2020 Oct 21. PMID: 33085496; PMCID: PMC7846975. doi:10.1152/ajpcell.00277.2020
- Sveiven, S. N., and Nordgren, T. M. (2020). Lung-resident Mesenchymal Stromal Cells Are Tissue-specific Regulators of Lung Homeostasis. *Am. J. Physiol. - Lung Cell Mol. Physiol.* 319 (2), L197–L210. doi:10.1152/AJPLUNG.00049.2020
- Sun, T., Huang, Z., Zhang, H., Posner, C., Posner, G., and Ramalingam, T. R. (2019). TAZ is Required for Lung Alveolar Epithelial Cell Differentiation After Injury. *JCI Insight* 5, e128674. doi:10.1172/jci.insight.128674
- Takezaki, A., Tsukumo, S., Setoguchi, Y., Ledford, J. G., Goto, H., Hosomichi, K., et al. (2019). A Homozygous SFTPA1 Mutation Drives Necroptosis of Type II Alveolar Epithelial Cells in Patients with Idiopathic Pulmonary Fibrosis. *J. Exp. Med.* 216 (12), 2724–2735. doi:10.1084/jem.20182351
- Tashiro, J., Elliot, S. J., Gerth, D. J., Xia, X., Pereira-Simon, S., Choi, R., et al. (2015). Therapeutic Benefits of Young, but Not Old, Adipose-Derived Mesenchymal Stem Cells in a Chronic Mouse Model of Bleomycin-Induced Pulmonary Fibrosis. *Transl. Res.* 166, 554–567. doi:10.1016/j.trsl.2015.09.004
- Tong, L., Zhou, J., Rong, L., Seeley, E. J., Pan, J., Zhu, X., et al. (2016). Fibroblast Growth Factor-10 (FGF-10) Mobilizes Lung-Resident Mesenchymal Stem Cells and Protects against Acute Lung Injury. *Scientific Rep.* 6 (September), 1–12. doi:10.1038/srep21642
- Tzouveleakis, A., Paspaliaris, V., George, K., Ntoliou, P., Bouros, E., Oikonomou, A., et al. (2013). A Prospective, Non-randomized, No Placebo-Controlled, Phase Ib Clinical Trial to Study the Safety of the Adipose Derived Stromal Cells-Stromal Vascular Fraction in Idiopathic Pulmonary Fibrosis. *J. Transl Med.* 11, 171. doi:10.1186/1479-5876-11-171
- Uccelli, A., Moretta, L., and Pistoia, V. (2008). Mesenchymal Stem Cells in Health and Disease. *Nat. Rev. Immunol.* 8 (9), 726–736. doi:10.1038/nri2395
- Ulke, H. M., Mutze, K., Lehmann, M., Wagner, D. E., Heinzemann, K., Günther, A., et al. (2019). The Oncogene ECT2 Contributes to a Hyperplastic, Proliferative Lung Epithelial Cell Phenotype in Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Cell Mol. Biol.* 61 (6), 713–726. doi:10.1165/rcmb.2019-0047OC
- Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., James, J., and Lee, O. (2007). Exosome-mediated Transfer of mRNAs and microRNAs Is a Novel Mechanism of Genetic Exchange between Cells. *Nat. Cell Biol.* 9 (6), 654–659. doi:10.1038/ncb1596
- Vaughan, A. E., Brumwell, A. N., Xi, Y., Gotts, J. E., Brownfield, D. G., Treutlein, B., et al. (2015). Lineage-negative Progenitors Mobilize to Regenerate Lung Epithelium after Major Injury. *Nature* 517 (7536), 621–625. doi:10.1038/nature14112
- Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., et al. (2017). Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-step Transformation by KRAS Mutations. *Cancer Cell* 32 (3), 360–376.e6. doi:10.1016/j.ccell.2017.08.006
- Vishnubhatla, L., Randolph, C., Stevanato, L., Hicks, C., and Sinden, J. (2014). The Development of Stem Cell-Derived Exosomes as a Cell-free Regenerative Medicine. *J. Circulating Biomarkers* 3, 1–14. doi:10.5772/58597
- Vizoso, F. J., Eiro, N., Cid, S., Schneider, J., and Perez-Fernandez, R. (2017). Mesenchymal Stem Cell Secretome: Toward Cell-free Therapeutic Strategies in Regenerative Medicine. *Int. J. Mol. Sci.* 18 (9), 1852. doi:10.3390/ijms18091852
- Wang, H., Yang, Y. F., Zhao, L., Xiao, F. J., Zhang, Q. W., Wen, M. L., et al. (2013). Hepatocyte Growth Factor Gene-Modified Mesenchymal Stem Cells Reduce Radiation-Induced Lung Injury. *Hum. Gene Ther.* 24 (3), 343–353. Epub 2013 Mar 4. PMID: 23458413. doi:10.1089/hum.2012.177
- Wang, L., Yuan, Y., Yang, X., Fan, T., Mei, B., Hou, J., et al. (2017). Platelet Derived Growth Factor Alpha (PDGFR α) Induces the Activation of Cardiac Fibroblasts by Activating C-Kit. *Med. Sci. Monitor* 23, 3808–3816. doi:10.12659/MSM.906038
- Wang, S., Hu, B., Ding, Z., Dang, Y., Wu, J., Li, D., et al. (2018). ATF6 Safeguards Organelle Homeostasis and Cellular Aging in Human Mesenchymal Stem Cells.

- Cell Discov* 4, 2, 2018. PMID: 29423270; PMCID: PMC5798892. doi:10.1038/s41421-017-0003-0
- Weiss, D. J., and Ortiz, L. A. (2013). Cell Therapy Trials for Lung Diseases: Progress and Cautions. *Am. J. Respir. Crit. Care Med.* 188 (2), 123–125. doi:10.1164/rccm.201302-0351ED
- Willis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., Roland, M., et al. (2005). Induction of Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells by Transforming Growth Factor- β 1: Potential Role in Idiopathic Pulmonary Fibrosis. *Am. J. Pathol.* 166 (5), 1321–1332. doi:10.1016/S0002-9440(10)62351-6
- Wipff, P. J., Rifkin, D. B., Jean, J. M., and Hinz, B. (2007). Myofibroblast Contraction Activates Latent TGF- β 1 from the Extracellular Matrix. *J. Cell Biol.* 179 (6), 1311–1323. doi:10.1083/jcb.200704042
- Worthington, E. N., and Hagood, J. S. (2020). Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease. *Int. J. Mol. Sci.* 21 (7). doi:10.3390/ijms21072318
- Wu, H., and Tang, N. (2021). Stem Cells in Pulmonary Alveolar Regeneration. *Development* 148 (2), dev193458. doi:10.1242/dev.193458
- Xie, T., Liang, J., Liu, N., Huan, C., Zhang, Y., Liu, W., et al. (2016). Transcription Factor TBX4 Regulates Myofibroblast Accumulation and Lung Fibrosis. *J. Clin. Invest.* 126 (8), 3063–3079. doi:10.1172/JCI85328
- Xu, C., Wang, J., Zhu, T., Shen, Y., Tang, X., Fang, L., et al. (2016a). Cross-Talking between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation. *Curr. Stem Cell Res Ther* 11 (3), 247–254. PMID: 26201865. doi:10.2174/1574888x10666150723145707
- Xu, Y., Mizuno, T., Sridharan, A., Du, Y., Guo, M., Tang, J., et al. (2016b). Single-cell RNA Sequencing Identifies Diverse Roles of Epithelial Cells in Idiopathic Pulmonary Fibrosis. *JCI Insight* 1 (20), e90558. doi:10.1172/jci.insight.90558
- Yamada, M., Kubo, H., Kobayashi, S., Ishizawa, K., Numasaki, M., Ueda, S., et al. (2004). Bone Marrow-Derived Progenitor Cells Are Important for Lung Repair after Lipopolysaccharide-Induced Lung Injury. *J. Immunol.* 172 (2), 1266–1272. doi:10.4049/jimmunol.172.2.1266
- Yao, C., Guan, X., Carraro, G., Parimon, T., Liu, X., Huang, G., et al. (2020). Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* 203 (6), 707–717. doi:10.1164/rccm.202004-1274oc
- Yu, S., Liu, L.-J., Lv, B., Che, C.-li., Fan, D.-P., Wang, L.-F., et al. (2015). Inhibition of Bleomycin-Induced Pulmonary Fibrosis by Bone Marrow-Derived Mesenchymal Stem Cells Might Be Mediated by Decreasing. *Cell Biochem Funct* 33 (6), 356–366. July. doi:10.1002/cbf.3118
- Zacharias, W. J., Frank, D. B., Zepp, J. A., Morley, M. P., Alkhaleel, F., Kong, J., et al. (2018). *HHS Public Access* 555 (7695), 251–255. doi:10.1038/nature25786.Regeneration
- Zakaria, D. M., Noha, M. Z., Samia, A. A. A., Radwa, A. M., and Rehab, A. M. (2021). Histological and Physiological Studies of the Effect of Bone Marrow-Derived Mesenchymal Stem Cells on Bleomycin Induced Lung Fibrosis in Adult Albino Rats. *Tissue Eng. Regenerative Med.* 18 (1), 127–141. doi:10.1007/s13770-020-00294-0
- Zhang, E., Yang, Y. E., Zhang, J., Ding, G., Chen, S., Cheng, P., et al. (2019). Efficacy of Bone Marrow Mesenchymal Stem Cell Transplantation in Animal Models of Pulmonary Fibrosis after Exposure to Bleomycin: A Meta-Analysis. *Exp. Ther. Med.* 17 (3), 2247–2255. doi:10.3892/etm.2019.7205
- Zhang, H. Y., Gharaee-Kermani, M., Zhang, K., Karmiol, S., and Sem, H. (1996). Lung Fibroblast α -smooth Muscle Actin Expression and Contractile Phenotype in Bleomycin-Induced Pulmonary Fibrosis. *Am. J. Pathol.* 148 (2), 527–537.
- Zhou, B., Liu, Y., Kahn, M., David, K. A., Han, A., Wang, H., et al. (2012). Interactions between β -Catenin and Transforming Growth Factor- β Signaling Pathways Mediate Epithelial-Mesenchymal Transition and Are Dependent on the Element-Binding Protein (CREB)-binding Protein (CBP). *J. Biol. Chem.* 287 (10), 7026–7038. doi:10.1074/jbc.M111.276311
- Zumla, A., Fu, S. W., Chang, C., Giuseppe, I., Petrosillo, N., Agrati, C., et al. (2020). Reducing Mortality and Morbidity in Patients with Severe COVID-19 Disease by Advancing Ongoing Trials of Mesenchymal Stromal (Stem) Cell (MSC) Therapy — Achieving Global Consensus and Visibility for Cellular Host-Directed Therapies. *Int. J. Infect. Dis.* 96, 431–439. doi:10.1016/j.ijid.2020.05.040
- Zysman, M., Baptista, B. R., Essari, L. A., Taghizadeh, S., Thibault de Ménonville, C., Giffard, C., et al. (2020). Targeting p16INK4a Promotes Lipofibroblasts and Alveolar Regeneration after Early-Life Injury. *Am. J. Respir. Crit. Care Med.* 202 (8), 1088–1104. PMID: 32628504. doi:10.1164/rccm.201908-1573OC

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Samarelli, Tonelli, Heijink, Martin Medina, Marchioni, Bruzzi, Castaniere, Andrisani, Gozzi, Manicardi, Moretti, Cerri, Fantini, Tabbi, Nani, Mastroli, Weiss, Dominici and Clini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

GLOSSARY

- IPF** idiopathic pulmonary fibrosis
- IIPs** idiopathic interstitial pneumonias
- MSCs** mesenchymal stem cells
- ECT2** epithelial cell transforming sequence 2
- AECI** alveolar epithelial cells 1
- AECII** alveolar epithelial cell 2
- AEP** alveolar epithelial progenitor
- TGF- β 1** transforming growth factor beta 1
- PDGF** platelet-derived growth factor
- VEGF** vascular endothelial growth factor
- FGF** fibroblast growth factor
- IL-1** interleukin 1
- TNF- α** tumor necrosis factor-alpha
- ERS** endoplasmic reticulum stress
- EMMPRIN** extracellular matrix metalloproteinase inducer
- CXCL12** C-X-C motif chemokine 12
- CCL2** chemokine C-C motif ligand 2
- EMT** epithelial mesenchymal transition
- α -SMA** alpha smooth-muscle actin
- Shh** sonic hedgehog
- PTEN** phosphatase and tensin homologuephosphatase and TENsin homolog
- INF γ** interferon γ
- PDGFR α** platelet-derived growth factor receptor A
- ABCA3** ATP binding cassette subfamily A member 3
- DKC1** dyskerin pseudouridine synthase 1
- TP53** tumor protein P53
- TOLIP** toll interacting protein
- MUC5B** mucin 5B
- ECM** extracellular matrix
- BM** bone marrow
- hMSCs** human mesenchymal stem cells
- KGF** keratinocyte growth factor
- ARDS** acute respiratory distress syndrome
- Thy-1 or CD90** cluster of differentiation 90
- BAL** bronchoalveolar Lavage
- SASP** senescence associated secretory phenotype
- uMSCs** umbilical cord derived Mesenchymal Stem Cells
- DLCO** diffuse lung coefficient for carbon dioxide
- Igfb** insulin growth factor binding protein
- FVC** forced vital capacity
- CT** computed tomography
- ADMSCs** adipose tissue-derived mesenchymal stem cells
- GEF** guanine nucleotide exchange factor
- CTGF** connective tissue growth factor
- EV** extracellular vesicles
- PI3K** phosphatidylinositol 3-Kinase
- TCF** T cell factor
- miRNA** micro RNA
- MVs** micro vesicles
- MHC I** major histocompatibility complex I
- HGF** hepatoocyte growth factor
- IDO-1** indolamine 2,3-dioxygenase-1
- IL-1Ra** IL-1 receptor antagonist
- PGE2** prostaglandin E2
- PTEN** phosphatase and tensin homologuephosphatase and TENsin homolog
- NK** natural killer cells
- YAP** yes-associated protein
- TAZ** transcriptome coactivator with PDZ-binding motif
- ECs** endothelial cells
- GLI1** transcription factors glioma-associated homologue
- MHC-1** major histocompatibility complex I
- BLM** bleomycin
- CS** cigarette smoke
- SFPTA1** surfactant protein 1
- CDKN1A** cyclin dependent kinase inhibitor 1A
- TERT** telomerase reverse transcriptase
- MCC** mucociliary clearance
- MCP1** CCL2 monocyte chemotacticprotein 1
- SDF1** stromal cell-derived factor 1
- TIMP** tissue inhibitors of metalloproteinase
- BDNF** brain-derived neurotrophic factor
- NGF** nerve growth factor
- CINC-1** cytokine-induced neutrophil chemoattractant 1
- AT-MSCs** adipose tissue-derived mesenchymal stem cells
- COPD** chronic obstructive pulmonary disease
- LSC-Sec** lung spheroid cell-secretome
- LSC-Exo** lung spheroid cell exosomes
- lncRNAs** long non coding RNA